JP3585238B2 - 真核細胞における部位特異的突然変異誘発のための化合物および方法 - Google Patents
真核細胞における部位特異的突然変異誘発のための化合物および方法 Download PDFInfo
- Publication number
- JP3585238B2 JP3585238B2 JP51636795A JP51636795A JP3585238B2 JP 3585238 B2 JP3585238 B2 JP 3585238B2 JP 51636795 A JP51636795 A JP 51636795A JP 51636795 A JP51636795 A JP 51636795A JP 3585238 B2 JP3585238 B2 JP 3585238B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- region
- chimeric
- regions
- strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 26
- 210000003527 eukaryotic cell Anatomy 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 title description 2
- 238000002741 site-directed mutagenesis Methods 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 63
- 108020004707 nucleic acids Proteins 0.000 claims description 63
- 150000007523 nucleic acids Chemical class 0.000 claims description 63
- 230000035772 mutation Effects 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000006798 recombination Effects 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 238000010396 two-hybrid screening Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 abstract description 9
- 125000002652 ribonucleotide group Chemical group 0.000 abstract description 9
- 108091028664 Ribonucleotide Proteins 0.000 abstract description 8
- 239000002336 ribonucleotide Substances 0.000 abstract description 8
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 7
- 239000005547 deoxyribonucleotide Substances 0.000 abstract description 7
- 125000002637 deoxyribonucleotide group Chemical group 0.000 abstract description 7
- 108091033319 polynucleotide Proteins 0.000 abstract description 7
- 102000040430 polynucleotide Human genes 0.000 abstract description 7
- 239000002157 polynucleotide Substances 0.000 abstract description 5
- 230000004075 alteration Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 41
- 238000002744 homologous recombination Methods 0.000 description 16
- 230000006801 homologous recombination Effects 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 102000053642 Catalytic RNA Human genes 0.000 description 7
- 108090000994 Catalytic RNA Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003471 mutagenic agent Substances 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 102000001218 Rec A Recombinases Human genes 0.000 description 4
- 108010055016 Rec A Recombinases Proteins 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical class OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 241000221566 Ustilago Species 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 108091027305 Heteroduplex Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- KDELTXNPUXUBMU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid boric acid Chemical compound OB(O)O.OB(O)O.OB(O)O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KDELTXNPUXUBMU-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101710193739 Protein RecA Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000301083 Ustilago maydis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- -1 nucleic acid compounds Chemical class 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Description
本発明は、分子遺伝学の分野に関するものである。特に、本発明は、生存している培養真核細胞に特定の遺伝的変異を導入するための核酸化合物ならびにその使用方法に関する。より詳細には、本発明は、二本鎖核酸の1本の鎖の一部が2'−Oまたは2'−OMeリボースを含むヌクレオチドからなり、残りの部分がデオキシリボースヌクレオチドからなる、実質的にワトソン・クリック型塩基対を形成した二本鎖核酸に関する。
2.発明の背景
2.1. キメラおよび/またはハイブリッド二本鎖核酸
本発明の分野は核酸に関するものである。核酸はヘテロポリマー、すなわち、配向されたホスホジエステル結合またはその誘導体によってポリマーへと連結されている、同一でないサブユニットのポリマーである。二本鎖核酸とは、ウラシルまたはチミンに対してはアデニン、シトシンに対してはグアニンという塩基対の法則に従って、二本鎖の第一鎖の各塩基が二本鎖の第二鎖の塩基に対応している核酸のことである。こうした対応(correspondence)を有する逆平行二本鎖はワトソン・クリック型対合(Watson−Crick pairing)をしていると言われる。二本鎖核酸には主に2つのタイプがあり、リボ核酸とデオキシリボ核酸である。それぞれのリボヌクレオチドには同様のデオキシリボヌクレオチドがあり、例えば、アデノシンとデオキシアデノシン、シチジンとデオキシシチジン、グアノシンとデオキシグアノシン、ウリジンとチミジンである。この分野において、リボヌクレオチドとデオキシリボヌクレオチドの両方が同一の鎖に存在している核酸は混合またはキメラ(以後「キメラ」と言う)核酸と称される。デオキシリボヌクレオチドとリボヌクレオチドが互いに対応している二本鎖核酸はハイブリッド二本鎖と呼ばれる。2本の鎖がそれらの塩基の一部において二本鎖核酸の領域を形成している場合、生ずる分子はヘテロ二本鎖と称される。
たいていの場合、二本鎖核酸の2本の鎖は共有結合しておらず、ワトソン・クリック型対合によってのみ結びついている。しかしながら、二本鎖の2本の鎖をオリゴヌクレオチドにより連結させて一本鎖ポリマーを形成することができる。リンキングオリゴヌクレオチドはワトソン・クリック型塩基対を形成しない。第一鎖と第二鎖が一本鎖ポリマーの一部であるヘテロ二本鎖は「ヘアピン二本鎖」または「ステム・ループ(stem and loop)」構造と呼ばれる。以後、前者の用語を用いることにする。
ここで用いるキメリズム(chimerism)は核酸ポリマーの特性であり、そしてハイブリディズム(hybridism)は二本鎖の特性である。例えば、mRNAとその鋳型はどちらもキメラではないがハイブリッド二本鎖を形成し、一方、例えば、キメラオクタヌクレオチド5'd(TTTT)−r(CCCC)3'および5'r(GGGG)−d(AAAA)3'は互いとワトソン・クリック型二本鎖を形成するであろうが、得られる二本鎖はハイブリッド二本鎖ではない。ハイブリッド二本鎖ではない二本鎖核酸を以後「ホモ二本鎖」と呼ぶことにする。特にことわらないかぎり、ホモ二本鎖核酸はデオキシヌクレオチド含有二本鎖のことである。なお、当業者はワトソン・クリック型二本鎖の形成を「ハイブリダイゼーション(ハイブリッド形成)」と呼んでいるが、その場合でさえハイブリッド二本鎖核酸は存在しないことに注意されたい。
X線回折および二次元NMRによるキメラおよび/またはハイブリッド二本鎖核酸の構造の研究に関心のある人達は、彼らの研究に使用するためのキメラ核酸およびハイブリッド二本鎖核酸を合成してきた。例えば、Salazar,M.ら,1994,J.Mol.Biol.241:440−55およびEgli,M.ら,1993,Biochemistry 32:3221−37(r3d7・d10型のキメラハイブリッド二本鎖);Ban,C.ら,1994,J.Mol.Biol.236;275−85(d5r1d4型の自己相補的キメラハイブリッド二本鎖);Chou,S.H.,1991,Biochemistry 30:5248−57(d4r4d4型の自己相補および非自己相補キメラハイブリッド二本鎖)を参照のこと。これらの二本鎖核酸の相補鎖は互いに共有結合で結びついているのではなく、ワトソン・クリック型対合によってのみ結びついていた。
キメラ核酸を合成した第二グループの科学者達は、リボザイム、すなわち自己開裂性であるかまたは他のRNAを開裂するRNA分子、の研究および使用に関心のある人達であった。Perreault,J.P.ら,1990,Nature 344:565;Taylor,N.R.ら,1992,Nucleic Acids Research 20:4559−65;Shimaya T.,1993,Nucleic Acids Research 21:2605を参照のこと。これらの研究者らは、キメラリボザイムが活性であって、しかもRNAリボザイムよりもヌクレアーゼ消化に対して抵抗することを見いだした。キメラリボザイムは自己相補的であり、つまり、ワトソン・クリック型対合鎖が共有結合で結びついている。キメラリボザイムの研究に際して合成された化合物は、キメラリボザイムが安定したハイブリッド二本鎖を含まないという点で、構造研究のために合成され使用された上記のハイブリッド二本鎖分子とは相違している。こうして、DNA結合アームを有するキメラリボザイムがその基質に結合してハイブリッド二本鎖を形成する。Yang,J.H.ら.1990,Biochemistry 29:11156−60を参照のこと。また、Sawata,S.ら,1993,Nucleic Acids Research 21:5656−60;Hendry,P.ら,1992,Nucleic Acids Research 20:5737−41;Shimayama,T.ら,1993,Nucleic Acids Research 21:2605も参照のこと。リボザイムはRNA基質の開裂を触媒し、それゆえハイブリッド二本鎖が溶解される。
2.2. 真核細胞における部位特異的遺伝的変異
分子生物学の分野に習熟した人達は、多くの場合に、単に新しいポリ核酸配列(すなわち、新しい遺伝子)を標的真核細胞の中に導入するのではなく、むしろ標的細胞中の特定の既存遺伝子を改変することが望まれていることを認識している。標的細胞は培養下で用いたり、またはトランスジェニック動物を作出するために用いることができる。
培養下の真核細胞にDNAを導入するための様々な技法が開発されている。こうした技法として、リン酸カルシウム沈殿およびDEAE−デキストラン媒介エンドサイトーシス、エレクトロポレーション、リポソーム媒介融合、そして複製能のないウイルスによる形質導入が挙げられる。しかし、このような技法は真核細胞に機能性遺伝子を導入することはできても、特定の既存遺伝子に変化(突然変異)を簡単に導入することはできない。導入後、外因性DNAは、相同的組換えにより特定位置にではなく、非正統的組換え(illegitimate recombination)により細胞ゲノムの不特定位置に隔離される。
現在まで、高等真核細胞、すなわち哺乳動物細胞またはトリ細胞に、特定部位のまたは部位特異的な遺伝的変異(突然変異誘発)を導入するための一般的に満足のゆく方法は存在していない。高等真核細胞においては非常に長い(>1kb)核酸の導入による相同的組換えが可能であるが、これらの技法には入念な選択技術の使用が必要となる。なんとなれば、高等真核細胞における非正統的組換え率は相同的組換え率を上回るからである。Thomas,K.R.& Capecchi,M.R.,1987,Cell 52:503を参照のこと。さらに、Valancius,V.& Smithies O.,1991,Mol.Cell.Biol.11:4389(真核細胞における線状化プラスミドとスーパーコイルドプラスミドの相同的組換えの比較)を参照のこと。
部位特異的突然変異誘発を達成するための一つのアプローチは、細胞の中に直接一本鎖オリゴデオキシヌクレオチドを導入することであった。この手法は酵母Saccharomyces cerevisiaeにおいて成功裏に採用され、酵母では相同的組換えが高等真核細胞中よりも著しく活発に起こった。Moerschell,R.P.ら,1988,Proc.Natl.Acad.Sci.85:524−28;Yamamoto,T.ら,1992,Yeast 8:935−48を参照のこと。しかし、今日まで、一本鎖オリゴヌクレオチドを用いた哺乳動物細胞またはトリ細胞の形質転換が成功したという報告は皆無である。
標的DNAの構造と哺乳動物における相同的組換え率との関係は、交互のプリンおよびピリミジン塩基の領域、すなわち[d(TG)30・d(AC)30]が組換え率を表すということを示した研究によって推論し得る。これらの成果は培養哺乳動物細胞中の非複製プラスミドの研究において実証された。Wahls,W.P.ら,1990,Mol.Cell.Biol.10:785−93を参照のこと。こうした実験が外因性核酸と細胞ゲノムとの組換えを明らかにするまで拡張されることはなかった。
大腸菌において相同的組換えを促進するタンパク質RecAを用いて真核細胞での相同的組換えを促進させようとする試みがなされた。しかし、こうした試みは明らかに成功しなかった。例えば、W.Bertlingの米国特許第4,950,599号には、真核細胞中でRecAを用いても部位特異的突然変異率が極端に低いこと、そして相同的組換え率が向上しないことが記載されている。D.Zarling & E.Senaの特許公開WO 93/22443およびD.C.Gruenert & K.Kunzelmannの公開WO 94/04032は両方とも嚢胞性繊維症に関係した培養細胞系の遺伝的欠陥を修正することを記述している。これらの刊行物は主として操作方法に関するデータよりもむしろ原理を照明する実験データを載せている。こうして、核に接近させてポリヌクレオチド/RecA複合体を導入するために、ZarlingおよびGruenertは膜透過性にした細胞を利用しているが、こうした細胞は増殖能を持ち合わせていない。さらに、RecAにより促進された相同的組換えが無傷の細胞において起こったと主張する場合でさえ、これらの刊行物はその頻度の定量的概算値をまったく提示していない。かくして、原核生物RecAの使用は、生存真核細胞における相同的組換え率が相同的組換えの自然発生率よりも顕著に高いことを納得できる程度に明示していない。
3. 発明の概要
本発明は、デオキシリボヌクレオチドとリボヌクレオチドの両方を含み、対象の遺伝子と相同性の、単一の、共有結合で結びついた二本鎖オリゴヌクレオチドに関する。遺伝的変異を生み出すために、相同領域内に1個またはそれ以上の非対応(以後「異種」または「ミューテーター」と言う)塩基対が存在する。相同的組換えの正常な構成的細胞過程は標的ゲノム部位にミューテーターヌクレオチドを挿入させる。本発明の二本鎖オリゴヌクレオチド(以後「キメラベクター」と言う)は、対象となる遺伝子に異種塩基対を導入することによって該遺伝子を特異的に改変するために用いることができる。異種塩基対は対象の遺伝子と異なる塩基対、または対象の遺伝子に存在するものに加えた塩基対(挿入)であり得、また、異種塩基対は対象の遺伝子中に存在する塩基対の非存在(欠失)であり得る。本発明は、幾分かは、ベクター中に約15〜50塩基対のハイブリッド二本鎖核酸の領域を含めると、対象遺伝子の変異率が非常に増加するという知見に基づいている。異種塩基対の領域が1〜50塩基対である場合、異種塩基対は本発明のベクター中にホモ二本鎖かハイブリッド二本鎖のどちらかとして存在し得る。異種塩基対が50塩基対より長い場合、それらはホモ二本鎖として存在することが好適である。
ベクターは、真核細胞への核酸の導入を可能にする任意の公知方法によって標的細胞の中に導入することができる。理論によって拘束されないが、キメラベクターは、標的細胞の組換え/修復機構によって取り込まれ、遺伝子変換または相同的組換えにより標的遺伝子を変化させると考えられる。
【図面の簡単な説明】
図1は、2つのキメラベクターの模式図を示す。符号の説明は次のとおりである。1:第一鎖、2:第二鎖、3:異種領域、4:相同領域、5:リンカー、6:連結部位。
図1Aは、R−D−R型の連結されたキメラベクターである。
図1Bは、単一の3'および5'末端をもつR−D−R型のヘアピンキメラベクターである。
5. 発明の詳細な説明
5.1. 本発明のキメラベクターの説明
本発明は、デオキシリボース含有塩基とリボース含有塩基の両方を含む二本鎖核酸を意図している。それらはDNAとRNAの両領域を含み、それゆえ「キメラベクター」と称される。キメラベクターのリボヌクレオチドの2'−Oはメチル化され得る。また、ホスホジエステルはどれもホスホロチオジエステルまたはメチホスホノジエステルで置換することができる。
本発明のキメラベクターは単一の核酸ポリマーである。従って、本発明のキメラベクターはワトソン・クリック型塩基対を形成していない少なくとも1塩基、通常は3または4塩基、の少なくとも1つの領域を含まねばならない。これらの不対領域はワトソン・クリック型塩基対の2本の鎖の間のリンカーとして利用される。不対ヌクレオチド領域を有する合成された他のキメラヌクレオチドと対照的に、キメラベクターは酵素活性がない。すなわち、それらは化学反応を触媒しないか、または、それら自体がATPのような生物学的エネルギー源の非存在下で化学反応を受ける。
好ましい実施態様では、リンカーの塩基はデオキシリボヌクレオチドである。ポリマーの3'および5'末端が相補鎖の隣接ヌクレオチドにワトソン・クリック型塩基対合されるように、2つのリンカーをもつキメラベクターを構築することができる。その後、それらは、キメラベクターが単一の連続した環状核酸ポリマーを形成するように連結させることができる。
キメラベクターの残っている実質的に全部の塩基はワトソン・クリック型塩基対を形成する。ここで用いる「塩基がワトソン・クリック型対合する」または「それらが二本鎖核酸を形成する」という記述は、適当な温度および塩条件下でそれらが塩基対または二本鎖核酸を形成しうることを意味すると理解すべきである。いくつかの低塩および/または高温条件下では、ワトソン・クリック型塩基対が熱力学的に安定であることをやめて、二本鎖核酸が融解または変性を起こしうると理解すべきである。また、1個または2個の塩基対ミスマッチは本発明の操作可能性に影響を及ぼさないことを認識すべきである。
本発明キメラベクターは、標的遺伝子に変化(突然変異)を特異的に導入することを目的としたものである。変換の遺伝子部位は、標的部位の配列と同じ(相同である)配列(以後、相同領域と言う)をもつようにキメラベクターの一部を選択することによって決定される。キメラベクター配列と標的遺伝子の間で異なる領域は異種領域と称される。キメラベクターは標的遺伝子に対して異種であるが、ベクターのこの領域においてヘテロ二本鎖でないことに注意されたい。本発明の好ましい実施態様によれば、各キメラベクターには介在異種領域に隣接する2つの相同領域が存在し、これら3つの領域はすべて単一の連続した二本鎖核酸中に存在する。さらに、本発明によれば、各相同領域はハイブリッド二本鎖核酸の部分を含んでいる。ハイブリッド二本鎖の部分は少なくとも4塩基対、好ましくは8塩基対、より好ましくは約20〜30塩基対でありうる。キメラベクターの機能は、3'および5'末端の互いへの連結を可能にするように配置された、ハイブリッド二本鎖の領域内のホモ二本鎖のジヌクレオチド塩基対によって影響されることはない。2つの相同領域の合計の鎖長は少なくとも20塩基対、好ましくは40〜60塩基対でありうる。
本発明によると、ホモ二本鎖核酸の領域はベクターのハイブリッド二本鎖/相同領域の間に配置することができる。介在するホモ二本鎖は異種領域を含むことができる。異種領域が約50塩基対以下、好ましくは約20塩基対以下である場合には、ホモ二本鎖領域の介在は任意である。異種領域が約20塩基対を越える場合は、異種領域を含むホモ二本鎖を介在させることが好適である。
5.2. 本発明のキメラベクターの構築
本発明のキメラベクターは任意の方法で合成することができる。キメラベクターの最も簡便な合成法は、固相DNA合成で用いる技法の変法によるものである。Caruthers,M.H.,1985,Science 230:281−85;Itakura,K.ら,1984,Ann.Rev/Biochem.53:523−56を参照のこと。RNAおよびキメラ核酸の合成を可能にする変法は、Scaringe,S.A.ら,1990,Nucleic Acids Research 18:5433−41;Usman,N.ら,1992,Nucleic Acids Research 20:6695−99;およびSwiderski,P.M.ら,1994,Anal.Biochem 216:83−88に記述されており、これらの全体を参考としてここに組み入れるものとする。キメラ核酸の合成に関する最近の進展は、Usman,N.& Cedergren,R.,1992,Trends Bioch.Sci.17:334−9に概説されている。
2つのハイブリッド二本鎖領域間にホモ二本鎖領域が介在したキメラベクターは半合成法を使って構築することができる。ヘアピンコンホメーションを有する2つの合成キメラポリ核酸を構築すべきである。2つの異なる制限酵素消化産物のオーバーラップに相補的なオーバーラップ付着末端をもつ、2つのキメラ核酸の遊離5'および3'末端を構築する。相補的な制限酵素消化末端をもつホモ二本鎖領域を用意する。クローン化DNA断片の両末端への制限酵素部位の付加は当業者によく理解された技法を用いて行うことができ、例えば、限定するものではないが、伸長プライマーを用いるPCR増幅または制限部位を含むリンカーの平滑末端連結がある。2つのキメラヌクレオチドとホモ二本鎖領域は通常の酵素法により連結させることができる。キメラオリゴヌクレオチドが両末端で連結された産物は、非変性条件下でTrisホウ酸EDTA緩衝液にて6%ポリアクリルアミドゲル中で電気泳動を行うことにより、不完全に反応した基質から分離することができる。線状のキャップされた分子は拘束されて、これらの条件下ではより遅く泳動する。
本発明においては自然界に存在するヌクレオチドのみを含むキメラベクターを使用することができる。約20リボヌクレオチドのハイブリッド二本鎖領域を含むキメラベクターは、in vitroでRNase Hに耐性であることが判明した。酵素分解に対する耐性は、リボヌクレオチドを2'−Oメチル化リボヌクレオチドで置換することによっても得られる。加えてまたは別途、核酸のホスホジエステル結合をホスホロチオジエステルで置換してもよい。Shimayama,T.ら,1993,Nucleic Acids Research 21:2605を参照のこと。アラビノース含有ヌクレオチドも使用できる。ここで用いる「核酸」という用語は、こうした修飾核酸を包含するものである。
5.3. 本発明のキメラベクターの使用
本発明のキメラベクターは、標的細胞のゲノムの特定位置に突然変異を起こさせるために使用される。標的細胞のゲノムの特定位置はその核酸配列(以後、標的配列と言う)によって定められる。本発明によると、ハイブリッド二本鎖のいくつかの領域の存在を別にすれば、相同領域が標的配列と同一であるキメラベクターが構築される。導入しようとする変化は異種領域によってコードされる。この変化は該配列の1個以上の塩基の変化または1個以上の塩基の付加でありうる。標的配列の変化が約20個以下の塩基の付加である場合、本発明はハイブリッド二本鎖の1つまたは2つの領域を使って実施できる。標的配列の変化が約50個以上の塩基の付加である場合は、異種領域をホモ二本鎖領域内に含ませることが好ましい。
本発明を実施するには、キメラベクターを標的細胞の核の中に導入することが必要である。こうした導入を起こさせる方法はどれも使用できる。かかる方法として、エレクトロポレーション、DEAE−デキストラン、リン酸カルシウム沈殿、リポソーム媒介融合(リポフェクション)、そして直接注入が挙げられる。エレクトロポレーションが特に適している。
本発明の一実施態様において、キメラベクターはトランスジェニック動物を作出するために用いられる。Brinster,R.L.ら,1989,Proc.Natl.Acad.Sci.86:7087に記載の方法に従って、卵の前核にキメラベクターを導入することができる。さらに、T.E.WagnerおよびP.C.Hoppeの米国特許第4,873,191号を参照のこと。上記文献の内容をそのままここに参考として組み入れるものとする。別法として、キメラベクターを胚性幹細胞に導入し、その胚性幹細胞と正常な芽細胞との凝集によってもキメラ動物を作ることができる。トランスジェニック動物は、Capecchi,M.R.,1989,Science 244:1288(その全体を参考としてここに組み入れる)に記載の方法に従って、キメラ動物の子孫として得ることができる。
エレクトロポレーションを用いると、10,000個の処理細胞につき1個程度の細胞が標的配列で特異的に突然変異を起こす(以後「形質転換された」と言う)。かくして、本発明の実施には、突然変異を起こしていない大多数の細胞の中から形質転換された細胞を選別する方法の使用が含まれる。一実施態様において、細胞の形質転換は生育に有利な性質を付与する。生育に有利な性質の非限定的な例として、薬剤耐性、生育調節の変更および代謝産物利用能の変更が挙げられる。別の実施態様では、選別方法としてネガティブ選別を用いる。この方法では、形質転換された細胞が選別条件下で増殖できなくなり、一方、非形質転換細胞は増殖中の細胞を選択的に破壊する条件にさらすことにより除かれる。
また、形質転換細胞は免疫蛍光で検出しうる細胞表面抗原の改変された表現型をもつことができ、この場合は蛍光活性化セルソーター(Fluorescence Activated Cell Sorter)を使って選別することができる。
トランスジェニック動物を前核注入により作出する場合のように、細胞の中にキメラベクターを導入する方法が直接注入である場合は、形質転換率が細胞10,000個につき1個より多くなる。その結果、選別の必要性がかなり軽減される。
一般に、キメラベクターの有効量はエレクトロポレーションで形質転換しようとする培養細胞100万個あたりキメラベクター10〜1000ngの範囲である。
6. 実施例
6.1. 実施例1:Ustilago菌におけるin vivo活性
野生型のUstilagoは機能性ura−3遺伝子(その産物はウラシル生合成経路の一部をなす)をもっている。野生型Ustilagoを5'−fluororotic acid(5FOA)培地で生育させると、細胞はウラシル生合成経路へのこの酸の取込みのために死滅する。ura−3遺伝子に突然変異が起こってura−3 mRNAが産生されなくなると、5FOA培地上でも細胞は生き残る。
内因性ura−3遺伝子の配列は当技術分野で知られている。一組の実験において、この配列の塩基358をチミジンからアデニンに変えた。この変異は機能不全タンパク質をもたらす。
キメラベクターを次のように合成した:
塩基358で突然変異を起こさせるためのベクター(358 RNAベクター):
358ベクターはヘアピンコンホメーションをとる。下線部分の塩基はリボ核酸残基を示す。太字はミューテーター(異種領域)を示す。イタリック体で記した「T」は不対合塩基を示す。
対照として使用するために、同一の配列をもつがリボ核酸を含まないベクターも構築した。このベクターではウラシルの代わりにチミジンが用いられた。
塩基358で突然変異を起こさせるための対照ベクター(DNA 358ベクター)
このベクターもヘアピンコンホメーションをとる。この場合も太字の残基がミューテーターである。
in vivo形質転換実験を行うにあたり、当技術分野で公知の方法に従ってU.maydis細胞(107個)から50μl形質転換緩衝液中106個の回収率でプロトプラストを作り、異なる量のキメラベクターまたは均質(DNAのみ)ベクターをプロトプラストと37℃で混合してトランスフェクトした。次に細胞を選択培地にまき、生存コロニー(形質転換体)の数を数えた。結果を以下の表に示す。
これらのデータは、RNA358ベクターによる細胞のトランスフェクションが対応するDNAベクターを用いたトランスフェクションよりも大幅に細胞の生存を高めることを示している。
6.2. NIH 3T3細胞の形質転換
NIH 3T3細胞は良性の(制御できる)増殖特性を有するヒト細胞である。悪性の(制御できない)増殖特性は、Gly12をThrで置き換えるがん遺伝子H−rasの単一の点突然変異によって付与される。かくして、突然変異G→T12は容易に選択可能な増殖特性の変化を生じさせる。Taparowsky,E.ら,1982,Nature 300:762;Sukumar S.ら,1983,Nature 306:658を参照のこと。
G→T12突然変異を誘導するために、次の配列を有するキメラベクターを構築した:
この配列は通常の一文字表記で表してある。更なる特徴として、RNAには下線が引いてあり、不対合塩基はイタリック体で、そしてミューテーター塩基は太字で示してある。環化後、キメラベクターは2つのトリチミジニル配列によって実質的に相補的な2つの鎖に分割され、そしてリボース含有ヌクレオチドはすべてこれら2つの鎖の一方にのみ存在することに注目されたい。
2'−OMeリボース塩基を用いて、4個のデオキシリボース残基に隣接する1つ(R)および2つ(R−D−R)のハイブリッド二本鎖領域をそれぞれ有する2つの型のキメラベクターを合成した。R−D−R型は上記の配列番号3に示され、R型は塩基6−9(CGAC)がデオキシヌクレオチドであったこと以外は同一である。5'および3'末端はデオキシヌクレオチドであることに注目されたい。組換えDNA法で用いるものと同じDNAリガーゼ法を用いて合成後のキメラベクターを環化させた。連結後、環化したキメラベクターをD600ゲル(AT Biochem,Malvern,PA)中での分離用電気泳動を2回繰り返すことにより基質から単離した。
対照のベクターは次のものであった:1)ハイブリッド二本鎖を欠いている同一の配列(データを示した、「ホモ二本鎖」);2)配列5'−GCCCACACCGACGGCGCCACCAC−3'(配列番号4)を有する不対合DNA(データを示した、「sDNA」);3)異種領域を含まない、それゆえミューテーターヌクレオチドを含まないキメラベクター(データを示さず)。
この実験はエレクトロポレーション法を使ってNIH 3T3細胞(1×106個)を形質転換することにより実施した。エレクトロポレーション後、細胞を4×103個/cm2の密度でまき、14日間培養した。フォーカス形成細胞をクリスタルバイオレットで染色して形質転換体を視覚化した。陽性対照として、H rasのT12型をコードするプラスミドpT24を用いた。この対照を用いて、トランスフェクトされたNIH 3T3細胞中における非正統的組換えレベルを測定した。実験を5回繰り返し、その結果を以下の表に要約して示す。以下に示した結果に加えて、ミューテーターコドンを含まないキメラベクターを使用した対照実験では、NIH 3T3細胞の形質転換フォーカスが全く現れなかった。
これらの結果から、キメラベクターは相同的組換えにより特定の突然変異を導入して哺乳動物細胞を形質転換したことがわかる。この実験での形質転換率は、全突然変異H−ras遺伝子を含むpT24陽性対照ベクターを用いたトランスフェクションにおいて観察された非正統的組換えによる形質転換率よりも高かった。かくして、キメラベクターを用いることにより、非正統的組換え率よりも高い、哺乳動物細胞での相同的組換え率が達成されたことになる。
配列表
配列番号:1
配列の長さ:37塩基対
配列の型:核酸
鎖の数:自己相補的(self complementary)
トポロジー:直鎖状
配列の種類:DNA/RNA
配列の特徴:
特徴を表す記号:−
存在位置:19..32
他の情報:/ラベル=a
/注=“RNA"
配列
配列番号:2
配列の長さ:37塩基対
配列の型:核酸
鎖の数:自己相補的
トポロジー:直鎖状
配列の種類:DNA
配列
配列番号:3
配列の長さ:53塩基対
配列の型:核酸
鎖の数:自己相補的
トポロジー:直鎖状
配列の種類:DNA/RNA
配列の特徴:
特徴を表す記号:−
存在位置:2..5
他の情報:/ラベル=b
/注=“RNA"
配列の特徴:
特徴を表す記号:−
存在位置:10..21
他の情報:/ラベル=d
/注=“RNA"
配列の特徴:
特徴を表す記号:−
存在位置:51..52
他の情報:/ラベル=f
/注=“RNA"
配列
配列番号:4
配列の長さ:23塩基対
配列の型:核酸
鎖の数:自己相補的
トポロジー:直鎖状
配列の種類:DNA
配列
Claims (4)
- 多くても1つの3'末端と1つの5'末端をもつキメラ核酸であって、
a.不対領域が前記の核酸を第一鎖と第二鎖に分離するように配置されている、連続した不対塩基の領域;
b.第一鎖の塩基が第二鎖の塩基に対応している、鎖長が少なくとも15塩基対のワトソン・クリック型塩基対を形成した核酸の領域;
を含んでなり、その際、
(i)第一鎖は2'−Oまたは2'−OMeリボースで構成された連続した少なくとも3ヌクレオチドの領域を含み、これらのヌクレオチドがハイブリッド二本鎖としてワトソン・クリック型塩基対を形成しており、
(ii)ワトソン・クリック型塩基対を形成した核酸の領 域は、標的遺伝子配列に相同な2つの領域を含み、これ ら2つの相同領域がハイブリッド二本鎖の部分を含み、 これらの相同領域の間には標的遺伝子配列に変異を引き 起こす配列を含む異種領域が介在している、
ことを特徴とするキメラ核酸。 - 第一鎖が2つのハイブリッド二本鎖領域を形成する2'−Oまたは2'−OMeリボースで構成された連続ヌクレオチドの2つの領域を含み、各ハイブリッド二本鎖領域は少なくとも4塩基対の長さであり、そして少なくとも1塩基対のホモ二本鎖の介在領域が2つのハイブリッド二本鎖領域間に配置されており、前記のホモ二 本鎖の介在領域が異種領域を含む、請求項1に記載のキメラ核酸。
- 核をもつ細胞または細胞集団のゲノムの標的配列に所定の変異を導入する方法であって、
a.標的配列に相同な2つの領域と、それらの間に配置された、前記の変異をコードする異種領域と、を含む請求項1または2に記載のキメラ核酸を用意し、
b.該キメラ核酸を該細胞の核内に維持して、該キメラ核 酸と前記の標的配列が遺伝的組換えを起こすようにする、
ことを含んでなる方法。 - 非ヒトトランスジェニック動物の作製に用いるための、請求項1または2に記載のキメラ核酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16430393A | 1993-12-09 | 1993-12-09 | |
US164,303 | 1993-12-09 | ||
PCT/US1994/014181 WO1995015972A1 (en) | 1993-12-09 | 1994-12-09 | Compounds and methods for site-directed mutations in eukaryotic cells |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09506511A JPH09506511A (ja) | 1997-06-30 |
JP3585238B2 true JP3585238B2 (ja) | 2004-11-04 |
Family
ID=22593886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51636795A Expired - Fee Related JP3585238B2 (ja) | 1993-12-09 | 1994-12-09 | 真核細胞における部位特異的突然変異誘発のための化合物および方法 |
Country Status (15)
Country | Link |
---|---|
US (3) | US5565350A (ja) |
EP (1) | EP0733059B1 (ja) |
JP (1) | JP3585238B2 (ja) |
KR (1) | KR100386337B1 (ja) |
CN (2) | CN1048254C (ja) |
AT (1) | ATE196311T1 (ja) |
AU (1) | AU691550B2 (ja) |
CA (1) | CA2178729A1 (ja) |
DE (2) | DE733059T1 (ja) |
DK (1) | DK0733059T3 (ja) |
ES (1) | ES2149962T3 (ja) |
GR (1) | GR3034988T3 (ja) |
NZ (1) | NZ278490A (ja) |
PT (1) | PT733059E (ja) |
WO (1) | WO1995015972A1 (ja) |
Families Citing this family (801)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2268476A1 (en) * | 1991-07-03 | 1998-04-30 | Hyal Pharmaceutical Corporation | Use of hyaluronan in gene therapy |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
IL107150A0 (en) * | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
JP3484197B2 (ja) | 1993-09-03 | 2004-01-06 | アイシス・ファーマシューティカルス・インコーポレーテッド | アミン誘導化ヌクレオシドおよびオリゴヌクレオシド |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US5731181A (en) * | 1996-06-17 | 1998-03-24 | Thomas Jefferson University | Chimeric mutational vectors having non-natural nucleotides |
US5760012A (en) * | 1996-05-01 | 1998-06-02 | Thomas Jefferson University | Methods and compounds for curing diseases caused by mutations |
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20030044941A1 (en) | 1996-06-06 | 2003-03-06 | Crooke Stanley T. | Human RNase III and compositions and uses thereof |
EP0931090B1 (en) * | 1997-03-03 | 2004-04-21 | Applera Corporation | Improved chimeric oligonucleotide vectors |
US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US6524613B1 (en) | 1997-04-30 | 2003-02-25 | Regents Of The University Of Minnesota | Hepatocellular chimeraplasty |
GB9711015D0 (en) * | 1997-05-28 | 1997-07-23 | Zeneca Ltd | Improvements in or relating to organic compounds |
CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
KR20010022652A (ko) * | 1997-08-05 | 2001-03-26 | 키메라젠, 인크. | 식물에서 국소적인 유전자변형을 유발하기 위한 혼성 이중나선올리고뉴클레오티드의 용도 |
US7102055B1 (en) | 1997-11-18 | 2006-09-05 | Pioneer Hi-Bred International, Inc. | Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant |
AU760113C (en) | 1997-11-18 | 2004-04-22 | Pioneer Hi-Bred International, Inc. | Compositions and methods for genetic modification of plants |
EP1032692A1 (en) | 1997-11-18 | 2000-09-06 | Pioneer Hi-Bred International, Inc. | Targeted manipulation of herbicide-resistance genes in plants |
EP0945507A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Mannheim Gmbh | Tumorspezifische Expressionskontrollregion und deren Verwendung |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
US6010907A (en) | 1998-05-12 | 2000-01-04 | Kimeragen, Inc. | Eukaryotic use of non-chimeric mutational vectors |
US6004804A (en) | 1998-05-12 | 1999-12-21 | Kimeragen, Inc. | Non-chimeric mutational vectors |
EP1080103A4 (en) * | 1998-05-21 | 2003-07-02 | Isis Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES |
CA2329252A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for topical delivery of oligonucleotides |
US6693185B2 (en) | 1998-07-17 | 2004-02-17 | Bayer Bioscience N.V. | Methods and means to modulate programmed cell death in eukaryotic cells |
DE19836098A1 (de) | 1998-07-31 | 2000-02-03 | Hoechst Schering Agrevo Gmbh | Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
JP2003523166A (ja) | 1998-09-29 | 2003-08-05 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
JP2002529094A (ja) | 1998-11-09 | 2002-09-10 | プランテック バイオテクノロジー ゲーエムベーハー | コメ由来核酸分子および改変デンプンの生産のためのその使用 |
US6438561B1 (en) * | 1998-11-19 | 2002-08-20 | Navigation Technologies Corp. | Method and system for using real-time traffic broadcasts with navigation systems |
US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US20030054390A1 (en) * | 1999-01-19 | 2003-03-20 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
EP1151409A1 (en) * | 1999-01-18 | 2001-11-07 | Maxygen, Inc. | Methods of populating data stuctures for use in evolutionary simulations |
US6917882B2 (en) * | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
ES2341217T3 (es) * | 1999-01-19 | 2010-06-17 | Maxygen, Inc. | Recombinacion de acidos nucleicos mediada por oligonucleotidos. |
US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
US6127124A (en) * | 1999-01-20 | 2000-10-03 | Isis Pharmaceuticals, Inc. | Fluorescence based nuclease assay |
WO2000061184A2 (en) * | 1999-04-08 | 2000-10-19 | Glenn Gregory M | Dry formulation for transcutaneous immunization |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
CA2370132C (en) | 1999-05-07 | 2012-01-24 | E. I. Du Pont De Nemours And Company | Auxin transport proteins |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6271360B1 (en) * | 1999-08-27 | 2001-08-07 | Valigen (Us), Inc. | Single-stranded oligodeoxynucleotide mutational vectors |
AR025996A1 (es) * | 1999-10-07 | 2002-12-26 | Valigen Us Inc | Plantas no transgenicas resistentes a los herbicidas. |
AU7875400A (en) | 1999-10-07 | 2001-05-10 | Valigen, Inc. | Compositions and methods for plant genetic modification |
US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
US7668658B2 (en) | 1999-10-13 | 2010-02-23 | Sequenom, Inc. | Methods for generating databases and databases for identifying polymorphic genetic markers |
US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
US7074983B2 (en) | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
US7820878B2 (en) * | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
AU1777301A (en) * | 1999-11-19 | 2001-05-30 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US20060134629A1 (en) * | 2000-03-20 | 2006-06-22 | Link Charles J | Methods and compositions for elucidating protein expression profiles in cells |
US6897020B2 (en) * | 2000-03-20 | 2005-05-24 | Newlink Genetics Inc. | Methods and compositions for elucidating relative protein expression levels in cells |
US6936467B2 (en) * | 2000-03-27 | 2005-08-30 | University Of Delaware | Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
IL151948A0 (en) * | 2000-03-27 | 2003-04-10 | Univ Delaware | Oligonucleotides for targeted alteration of a genetic sequence and methods utilizing the same |
EP1284985A2 (en) * | 2000-05-17 | 2003-02-26 | University Of Delaware | Plant gene targeting using oligonucleotides |
US6686188B2 (en) | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US6656700B2 (en) | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US20030017593A1 (en) * | 2000-06-05 | 2003-01-23 | Gamper Howard B. | Binary hybrid mutational vectors |
US7468475B2 (en) | 2000-06-16 | 2008-12-23 | Schmuelling Thomas | Method for modifying plant morphology, biochemistry and physiology |
US6958214B2 (en) | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
WO2002010364A2 (en) * | 2000-07-27 | 2002-02-07 | University Of Delaware | Methods for enhancing targeted gene alteration using oligonucleotides |
US6875907B2 (en) | 2000-09-13 | 2005-04-05 | Pioneer Hi-Bred International, Inc. | Antimicrobial peptides and methods of use |
WO2002026967A2 (en) * | 2000-09-25 | 2002-04-04 | Thomas Jefferson University | Targeted gene correction by single-stranded oligodeoxynucleotides |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
US7560622B2 (en) | 2000-10-06 | 2009-07-14 | Pioneer Hi-Bred International, Inc. | Methods and compositions relating to the generation of partially transgenic organisms |
CA2427322C (en) | 2000-12-22 | 2012-03-06 | Aurox Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells |
US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
WO2002059337A1 (en) * | 2001-01-26 | 2002-08-01 | Georgetown University School Of Medicine | Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof |
AU2002303176A1 (en) * | 2001-03-27 | 2002-10-15 | University Of Delaware | Genomics applications for modified oligonucleotides |
AU2002303262A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene shinc-1 and diagnostic and therapeutic uses thereof |
AU2002303261A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
AU2002305151A1 (en) * | 2001-04-06 | 2002-10-21 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
US20040063922A1 (en) * | 2001-04-17 | 2004-04-01 | Conrad Charles A. | Methods and compositions for catalytic DNA exchange in a sequence specific manner |
US20030045830A1 (en) * | 2001-04-17 | 2003-03-06 | De Bizemont Therese | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
US7053195B1 (en) | 2001-06-12 | 2006-05-30 | Syngenta Participatious Ag | Locked nucleic acid containing heteropolymers and related methods |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
KR100576674B1 (ko) | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
EP2270024B1 (en) | 2001-06-21 | 2018-10-24 | Ionis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP1925672A1 (en) | 2001-06-22 | 2008-05-28 | Syngeta Participations AG | Abiotic stress responsive polynucleotides and polypeptides |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
CA2455424A1 (en) * | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
WO2003013226A2 (en) * | 2001-08-09 | 2003-02-20 | Cibus Genetics | Non-transgenic herbicide resistant plants |
US7456335B2 (en) * | 2001-09-03 | 2008-11-25 | Basf Plant Science Gmbh | Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants |
EP2284195A1 (en) | 2001-09-18 | 2011-02-16 | Carnegie Institution Of Washington | Fusion proteins useful for detecting analytes |
NZ573742A (en) | 2001-09-18 | 2010-07-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT212 |
EP1448766A2 (en) * | 2001-09-27 | 2004-08-25 | University Of Delaware | Coisogenic eukaryotic cell collections |
WO2003027265A2 (en) * | 2001-09-27 | 2003-04-03 | University Of Delaware | Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration |
MXPA04002817A (es) | 2001-09-27 | 2004-07-05 | Pioneer Hi Bred Int | Polinucleotidos de fitato y metodos de uso. |
US7468244B2 (en) * | 2001-09-27 | 2008-12-23 | University Of Delaware | Polymorphism detection and separation |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
ATE516364T1 (de) | 2001-10-09 | 2011-07-15 | Isis Pharmaceuticals Inc | Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5 |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
JP2005525095A (ja) | 2002-01-02 | 2005-08-25 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
EP1465982A4 (en) | 2002-01-25 | 2006-06-07 | Gamida Cell Ltd | PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED |
JP2005515780A (ja) | 2002-02-01 | 2005-06-02 | セクイター インコーポレイテッド | 二本鎖オリゴヌクレオチド |
WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
US7135326B2 (en) * | 2002-02-07 | 2006-11-14 | E. I. Du Pont De Nemours And Company | UDP-glucosyltransferases |
AU2003211128A1 (en) | 2002-02-20 | 2003-09-09 | American Integrated Biologics, Inc. | Transgenic production in saliva |
CA2478479A1 (en) * | 2002-03-07 | 2003-09-18 | University Of Delaware | Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phagebeta protein, or hydroxyurea |
NZ535602A (en) | 2002-04-08 | 2006-07-28 | Pioneer Hi Bred Int | Enhanced silk exsertion under stress in Zea mays plants |
US7138512B2 (en) * | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
US7244565B2 (en) * | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2003093296A2 (en) | 2002-05-03 | 2003-11-13 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
AU2003245878B2 (en) | 2002-05-08 | 2008-01-24 | Basf Plant Science Gmbh | Methods for increasing oil content in plants |
US20030228317A1 (en) * | 2002-05-22 | 2003-12-11 | Prafulla Gokhale | Gene BRCC-1 and diagnostic and therapeutic uses thereof |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
US20030228558A1 (en) * | 2002-06-11 | 2003-12-11 | Bloom William Dennis | Method of training brokers in a multi-level marketing business |
AU2003231912A1 (en) * | 2002-06-12 | 2003-12-31 | Tel Aviv Medical Center Research Development Fund | Methods of detecting and treating prostate cancer |
EP1550463A4 (en) * | 2002-09-20 | 2006-12-27 | Dainippon Sumitomo Pharma Co | PREPARATION FOR FACILITATING SITECOUS GENERAL TRANSFORMATION AND PREPARATION FOR GENDER THERAPY |
US7229976B2 (en) | 2002-09-26 | 2007-06-12 | Isis Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
US20040175722A1 (en) * | 2002-10-07 | 2004-09-09 | Kmiec Eric B. | Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration |
EP1560839A4 (en) | 2002-11-05 | 2008-04-23 | Isis Pharmaceuticals Inc | CHIMERIC OLIGOMER COMPOUNDS AND THEIR USE IN GENE MODULATION |
US9150606B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
CA2502490A1 (en) * | 2002-11-08 | 2004-05-27 | Hematech, Llc | Transgenic ungulates having reduced prion protein activity and uses thereof |
SI1569695T1 (sl) | 2002-11-13 | 2013-08-30 | Genzyme Corporation | Protismiselna modulacija ekspresije apolipoproteina B |
JP4986109B2 (ja) | 2002-11-13 | 2012-07-25 | ジェンザイム・コーポレーション | アポリポタンパク質b発現のアンチセンス調節 |
EP1572971B1 (en) | 2002-11-15 | 2009-09-30 | Morphotek Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
AU2003293991B2 (en) | 2002-12-19 | 2009-01-22 | Bayer Intellectual Property Gmbh | Plant cells and plants which synthesize a starch with an increased final viscosity |
ES2400033T3 (es) | 2003-02-11 | 2013-04-05 | Antisense Therapeutics Ltd | Modulación de la expresión del receptor del factor de crecimiento I similar a la insulina |
WO2004074440A2 (en) | 2003-02-17 | 2004-09-02 | Metanomics Gmbh | Preparation of organisms with faster growth and/or higher yield |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
EP2390313B1 (de) | 2003-03-31 | 2016-05-11 | University Of Bristol | Neue pflanzliche Acyltransferase spezifisch für langkettige mehrfach ungesättigte Fettsäuren |
US20040205840A1 (en) * | 2003-04-11 | 2004-10-14 | Pioneer Hi-Bred International, Inc. | Method for reducing gene expression |
BRPI0409442A (pt) | 2003-04-15 | 2006-04-18 | Basf Plant Science Gmbh | célula vegetal transformada, planta transgênica, semente, molécula de ácido nucleico isolado, construção de ácido nucleico, vetor, célula hospedeira, proteìna relacionada com a tensão (srp) isolada, métodos de produzir uma planta transgênica com atividade metabólica alterada em comparação com uma célula vegetal do tipo selvagem não transformada correspondente e de modificar a toleráncia à tensão de uma planta, uso de um ácido nucleico que codifica srp e/ou de atividade metabólica alterada, célula vegetal, e, planta |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
EP1633307A4 (en) | 2003-06-03 | 2009-06-24 | Isis Pharmaceuticals Inc | MODULATION OF SURVIVIN EXPRESSION |
EP1644475A4 (en) * | 2003-06-20 | 2009-06-03 | Isis Pharmaceuticals Inc | DOUBLE-STRAND COMPOSITIONS WITH A 3'-ENDO-MODIFIED STRING FOR USE IN GENE MODULATION |
WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
EP2434019A1 (en) | 2003-08-01 | 2012-03-28 | BASF Plant Science GmbH | Process for the production of fine chemicals |
CA3037924A1 (en) | 2003-08-01 | 2005-02-10 | Basf Plant Science Gmbh | Method for the production of polyunsaturated fatty acids in transgenic organisms |
CA2534894C (en) | 2003-08-11 | 2020-01-21 | Kweek-En Researchbedrijf Agrico B.V. | Fungus resistant plants and their uses |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
EP2182063A3 (en) | 2003-09-18 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Modulation of EIF4E expression |
AU2004274021B2 (en) | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
ES2437491T3 (es) | 2003-10-10 | 2014-01-10 | Alchemia Oncology Pty Limited | Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad |
EP1689888A2 (en) | 2003-10-23 | 2006-08-16 | Illumigen Biosciences Inc. | Detection of mutations in a gene associated with resistance to viral infection, oas1 |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
PT2295073E (pt) | 2003-11-17 | 2014-07-16 | Genentech Inc | Anticorpo contra cd22 para o tratamento de tumor de origem hematopoiética |
US20050120397A1 (en) * | 2003-11-24 | 2005-06-02 | Hermann Steller | Compounds and methods for regulation of spermatid differentiation |
ES2372938T3 (es) | 2003-12-17 | 2012-01-27 | Cropdesign N.V. | Plantas que tienen características de crecimiento modificadas y método para preparar las mismas. |
US7741070B2 (en) | 2003-12-24 | 2010-06-22 | Massachusetts Institute Of Technology | Gene targets for enhanced carotenoid production |
US7695932B2 (en) * | 2003-12-24 | 2010-04-13 | Massachusetts Institute Of Technology | Gene targets for enhanced carotenoid production |
US7608699B2 (en) * | 2003-12-29 | 2009-10-27 | Rockefeller University | Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof |
US20050164271A1 (en) | 2004-01-20 | 2005-07-28 | Sanjay Bhanot | Modulation of glucocorticoid receptor expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
CA2556736C (en) | 2004-02-25 | 2013-02-19 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof |
CN1930277B (zh) | 2004-02-27 | 2011-02-02 | 巴斯福植物科学有限公司 | 在转基因植物中产生多不饱和脂肪酸的方法 |
EP1720988B1 (de) | 2004-02-27 | 2011-10-12 | BASF Plant Science GmbH | Verfahren zur herstellung von ungesättigten omega-3-fettsäuren in transgenen organismen |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US8790919B2 (en) * | 2004-03-15 | 2014-07-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNase H |
WO2005094370A2 (en) | 2004-03-29 | 2005-10-13 | The General Hospital Corporation | Oligonucleotide complex compositions and methods of use as gene alteration tools |
CA2561741C (en) | 2004-04-05 | 2016-09-27 | Alnylam Pharmaceuticals, Inc. | Processes and reagents for oligonucleotide synthesis and purification |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
EP1749102A4 (en) | 2004-04-22 | 2009-02-25 | Kirin Pharma Kk | TRANSGENIC ANIMALS AND USES THEREOF |
US20070072815A1 (en) * | 2004-05-04 | 2007-03-29 | Kmiec Eric B | Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration |
US7825293B2 (en) | 2004-05-28 | 2010-11-02 | Cropdesign N.V. | Plants having improved growth characteristics and a method for making the same |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
CA2735315A1 (en) | 2004-06-09 | 2005-12-29 | Pioneer Hi-Bred International, Inc. | Plastid transit peptides |
AU2005321630A1 (en) | 2004-07-02 | 2006-07-06 | Metanomics Gmbh | Process for the production of fine chemicals |
US8680062B2 (en) | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
EP2439211A1 (en) | 2004-07-12 | 2012-04-11 | CropDesign N.V. | Plants having improved growth characteristics and method for making the same |
WO2006013010A2 (en) | 2004-07-31 | 2006-02-09 | Metanomics Gmbh | Preparation of organisms with faster growth and/or higher yield |
DK2997980T3 (en) | 2004-08-10 | 2018-03-26 | Kastle Therapeutics Llc | PROCEDURES FOR MODULATING LIPROPROTEIN AND CHOLESTEROL LEVELS |
AU2005273864B2 (en) | 2004-08-16 | 2010-09-30 | Cropdesign N.V. | Plants having improved growth characteristics and method for making the same |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS |
WO2006034348A2 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
WO2006032708A2 (en) | 2004-09-24 | 2006-03-30 | Basf Plant Science Gmbh | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
JP2008516991A (ja) | 2004-10-20 | 2008-05-22 | アンチセンス セラピューティクス リミテッド | インテグリンα4発現のアンチセンス調節 |
DE602005025669D1 (de) | 2004-10-29 | 2011-02-10 | Cropdesign Nv | Pflanzen mit veränderten wachstumseigenschaften und verfahren zu deren herstellung |
EP2199304A1 (en) | 2004-12-17 | 2010-06-23 | Metanomics GmbH | Process for the control of production of fine chemicals |
AR051866A1 (es) | 2004-12-24 | 2007-02-14 | Cropdesign Nv | Plantas con aumento del rendimiento y metodo de prepracion |
EP1831376A1 (en) | 2004-12-28 | 2007-09-12 | Pioneer Hi-Bred International, Inc. | Improved grain quality through altered expression of seed proteins |
NZ556605A (en) | 2005-01-27 | 2010-03-26 | Cropdesign Nv | Plants having increased yield and a method for making the same |
EP2338905B1 (en) | 2005-02-23 | 2017-11-29 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes |
CA2598792A1 (en) | 2005-03-02 | 2006-09-08 | Metanomics Gmbh | Process for the production of fine chemicals |
EP2573188A2 (en) | 2005-03-02 | 2013-03-27 | Metanomics GmbH | Process for the production of fine chemicals |
BRPI0609283A2 (pt) | 2005-03-08 | 2010-11-23 | Basf Plant Science Gmbh | métodos para identificar um ìntron com propriedades intensificadoras de expressão em plantas, para enriquecer o número de ìntrons com propriedades intensificadoras de expressão em plantas, para isolar, fornecer ou produzir um ìntron com propriedades intensificadoras de expressão em plantas, para fornecer um cassete de expressão e para intensificar a expressão de uma seqüência de ácidos nucleicos em uma planta ou uma célula de planta, algoritmo de computador, dispositivo de computador ou dispositivo de armazenamento de dados, construto de expressão de dna recombinante, vetor de expressão, célula transgênica ou organismo não humano transgênico, cultura celular, partes ou material de propagação, e, uso de um organismo transgênico ou de culturas celulares, partes de material de propagação transgênico derivadas destas |
EP2050763A3 (en) | 2005-03-10 | 2009-07-15 | Genentech, Inc. | Methods and compositions for modulating vascular integrity |
DE102005013779A1 (de) | 2005-03-22 | 2006-09-28 | Basf Plant Science Gmbh | Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen |
EP1707632A1 (de) | 2005-04-01 | 2006-10-04 | Bayer CropScience GmbH | Phosphorylierte waxy-Kartoffelstärke |
CA2606270A1 (en) | 2005-04-19 | 2006-10-26 | Massachusetts Institute Of Technology | Amphiphilic polymers and methods of use thereof |
CA2604807C (en) | 2005-04-19 | 2018-06-12 | Basf Plant Science Gmbh | Improved methods controlling gene expression |
US20070011752A1 (en) * | 2005-05-06 | 2007-01-11 | American Integrated Biologics, Inc. | Production of human proteins in transgenic animal saliva |
WO2006127310A2 (en) | 2005-05-25 | 2006-11-30 | Pioneer Hi-Bred International, Inc. | Methods for improving crop plant architecture and yield |
US9505867B2 (en) | 2005-05-31 | 2016-11-29 | Ecole Polytechmique Fédérale De Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
AU2006260924B2 (en) | 2005-06-23 | 2011-03-03 | Basf Plant Science Gmbh | Improved methods for the production of stably transformed, fertile zea mays plants |
AR054161A1 (es) | 2005-07-06 | 2007-06-06 | Cropdesign Nv | Plantas con aumento del rendimiento y un metodo para prepararlas |
DE102005038036A1 (de) | 2005-08-09 | 2007-02-15 | Basf Plant Science Gmbh | Verfahren zur Herstellung von Arachidonsäure und/oder Eicosapentaensäure in transgenen Nutzpflanzen |
WO2007020198A2 (en) | 2005-08-12 | 2007-02-22 | Basf Plant Science Gmbh | Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress |
US7842856B2 (en) | 2005-08-25 | 2010-11-30 | The Board Of Trustees Of The University Of Illinois | Herbicide resistance gene, compositions and methods |
MX2008003389A (es) | 2005-09-15 | 2008-03-27 | Cropdesign Nv | Plantas que tienen rendimiento incrementado y un metodo para efectuar las mismas. |
CA2620387C (en) | 2005-09-20 | 2018-09-18 | Basf Plant Science Gmbh | Methods for controlling gene expression using ta-sirna |
US20100218271A1 (en) | 2005-10-05 | 2010-08-26 | Crop Design N.V. | Plants having improved characteristics and method for making the same |
GB2431158A (en) | 2005-10-13 | 2007-04-18 | Rothamsted Res Ltd | Process for the production of arachidonic and/or eicosapentaenoic acid |
WO2007051866A2 (en) | 2005-11-07 | 2007-05-10 | Cropdesign N.V. | Plants having improved growth characteristics and a method for making the same |
US8853492B2 (en) | 2005-11-07 | 2014-10-07 | Cropdesign N.V. | Plants having improved growth characteristics and a method for making the same |
CA2628505A1 (en) | 2005-11-08 | 2007-05-18 | Basf Plant Science Gmbh | Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants |
AR056790A1 (es) | 2005-11-08 | 2007-10-24 | Cropdesign Nv | Plantas con caracteristicas de crecimiento aumentado y un metodo para obtenerlas |
AR056778A1 (es) | 2005-11-10 | 2007-10-24 | Pioneer Hi Bred Int | Secuencias dof ( que se unen a adn con un dedo ) y metodos para usarlas |
US20070199096A1 (en) | 2005-11-14 | 2007-08-23 | E.I. Du Pont De Nemours And Company | Compositions and Methods for Altering Alpha- and Beta-Tocotrienol Content |
JP2009516710A (ja) | 2005-11-21 | 2009-04-23 | アイシス ファーマシューティカルズ, インコーポレーテッド | eIF4E−BP2の発現のモジュレート |
EP1957034A2 (de) * | 2005-11-24 | 2008-08-20 | Basf Se | Chimäre keratinbindende effektorproteine |
US7723574B2 (en) | 2005-11-24 | 2010-05-25 | Basf Plant Science Gmbh | Process for the production of Δ5-unsaturated fatty acids in transgenic organisms |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
EP2166086A3 (en) | 2005-12-01 | 2010-10-20 | CropDesign N.V. | Plants having improved growth characteristics and methods for making the same |
CN101341254A (zh) | 2005-12-24 | 2009-01-07 | 蒂加斯克乳制品研究中心 | 反-10,顺-12十八碳二烯酸的生产方法 |
CN101437933B (zh) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | 作为药物靶标的天然反义和非编码的rna转录物 |
US7592505B2 (en) | 2005-12-30 | 2009-09-22 | Pioneer Hi-Bred International, Inc. | UDP-xylose synthases (UXS) polynucleotides, polypeptides, and uses thereof |
RU2441366C2 (ru) | 2006-01-12 | 2012-02-10 | Сайбас Юроп Б.В. | Мутанты epsps |
AU2007204341B2 (en) | 2006-01-12 | 2012-10-04 | Basf Plant Science Gmbh | Use of stomatin (STM1) polynucleotides for achieving a pathogen resistance in plants |
PL3210633T3 (pl) | 2006-01-26 | 2019-12-31 | Ionis Pharmaceuticals, Inc. | Kompozycje i ich zastosowania ukierunkowane na huntingtynę |
US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
KR20130042043A (ko) | 2006-01-27 | 2013-04-25 | 아이시스 파마수티컬즈 인코포레이티드 | 6-변형된 바이시클릭 핵산 유사체 |
CA2640076C (en) | 2006-02-09 | 2013-09-24 | Pioneer Hi-Bred International, Inc. | Genes for enhancing nitrogen utilization efficiency in crop plants |
GB0603160D0 (en) | 2006-02-16 | 2006-03-29 | Rothamsted Res Ltd | Nucleic acid |
EP2343376A3 (en) | 2006-03-24 | 2011-11-23 | BASF Plant Science GmbH | Proteins associated with abiotic stress response and homologs |
EP2004829B1 (en) | 2006-03-31 | 2012-08-01 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
CA2644273A1 (en) | 2006-04-05 | 2008-03-27 | Metanomics Gmbh | Process for the production of a fine chemical |
BRPI0710455A2 (pt) | 2006-04-19 | 2011-08-16 | Pioneer Hi Bred Int | polipeptìdeo isolado, polinucleotìdeo isolado e métodos para aumentar o nìvel de um polipeptìdeo em uma planta, para modular o nìvel de um polipeptìdeo em uma planta e para modificar o crescimento de uma planta |
ATE514777T1 (de) | 2006-05-05 | 2011-07-15 | Isis Pharmaceuticals Inc | Verbindungen und verfahren zur modulation von genexpression |
US7547684B2 (en) | 2006-05-11 | 2009-06-16 | Isis Pharmaceuticals, Inc. | 5′-modified bicyclic nucleic acid analogs |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
EP2035562A2 (en) | 2006-05-30 | 2009-03-18 | CropDesign N.V. | Plants with modulated expression of extensin receptor-like kinase having enhanced yield-related traits and a method for making the same |
US20090300794A1 (en) | 2006-05-31 | 2009-12-03 | Metanomics Gmbh | Manipulation Of The Nitrogen Metabolism |
CN103215288A (zh) | 2006-06-08 | 2013-07-24 | 巴斯福植物科学有限公司 | 具有改良生长特性的植物及其制备方法 |
EP2599869A3 (en) | 2006-06-15 | 2013-09-11 | CropDesign N.V. | Plants having enhanced yield-related traits and a method for making the same |
BRPI0712507A2 (pt) | 2006-06-15 | 2011-07-05 | Cropdesign Nv | método para intensificar caracterìsticas relacionadas ao rendimento em plantas, planta ou parte da mesma, contrução uso de uma construção planta, parte de planta ou célula vegetal, método para a produção de uma planta transgência, partes colhìveis de um planta, produtos, uso de um ácido nucleico, molécula isolada de ácido nucleico, e, polipeptìdeo isolado |
AU2007265434B2 (en) | 2006-06-28 | 2012-08-02 | Cibus Europe B.V. | Fatty acid blends and uses therefor |
WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
ES2451669T3 (es) | 2006-08-02 | 2014-03-28 | Cropdesign N.V. | Plantas que tienen características mejoradas y un procedimiento de fabricación de las mismas |
EP2059600B1 (de) | 2006-08-30 | 2014-04-02 | BASF Plant Science GmbH | Verfahren zur erhöhung der pathogenresistenz in transgenen pflanzen |
US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
KR101449587B1 (ko) | 2006-09-14 | 2014-10-10 | 메드제닉스 메디칼 이스라엘 리미티드 | 장기 지속형 약물 제형 |
ES2531391T3 (es) | 2006-10-06 | 2015-03-13 | Basf Plant Science Gmbh | Delta-5 desaturasas y procedimiento para la preparación de ácidos grasos poliinsaturados en organismos transgénicos no humanos |
EP2487245A3 (de) | 2006-10-12 | 2012-10-24 | BASF Plant Science GmbH | Verfahren zur Erhöhung der Pathogenresistenz in transgenen Pflanzen |
US8344205B2 (en) | 2006-10-13 | 2013-01-01 | Basf Plant Science Gmbh | Plants with increased yield |
ES2389689T3 (es) | 2006-10-24 | 2012-10-30 | Basf Plant Science Gmbh | Método para incrementar la resistencia frente a hongos biotrópicos en vegetales |
US20100031389A1 (en) | 2006-11-16 | 2010-02-04 | Christophe Reuzeau | Plants Having Enhanced Yield-Related Traits And A Method For Making The Same Using Consensus Sequences From The Yabby Protein Family |
MX2009005280A (es) | 2006-11-24 | 2009-08-12 | Cropdesign Nv | Plantas transgenicas que comprenden como transgen un tcp clase i o clavata 1 (clv1) o polipeptido de cah3 que tienen un rendimiento aumentado de semillas y un metodo para generar las mismas. |
US20100024067A1 (en) | 2006-12-15 | 2010-01-28 | Cropdesign N.V. | Plants having enhanced seed yield-related traits and a method for making the same |
CN102676575B (zh) | 2006-12-21 | 2015-09-30 | 巴斯福植物科学有限公司 | 具有增强的产量相关性状的植物和用于产生该植物的方法 |
EP1935428A1 (en) * | 2006-12-22 | 2008-06-25 | Antisense Pharma GmbH | Oligonucleotide-polymer conjugates |
US7872170B2 (en) | 2006-12-28 | 2011-01-18 | Pioneer Hi-Bred International, Inc. | Genetic markers for orobanche resistance in sunflower |
EP2606903B1 (en) | 2007-01-10 | 2016-09-14 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
EP2057273A2 (en) | 2007-01-15 | 2009-05-13 | BASF Plant Science GmbH | Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants |
EP2548963A1 (en) | 2007-01-30 | 2013-01-23 | CropDesign N.V. | Plants having enhanced yield-related traits and a method for making the same |
BRPI0807047A2 (pt) | 2007-01-31 | 2014-04-22 | Basf Plant Science Gmbh | Método para o aumento da resistência ao estresse abiótico em plantas relativa as plantas de controle, e, usos de uma construção, e de um ácido nucleico que codifica um polipeptídeo semelhante a nap1. |
AU2008212820B2 (en) | 2007-02-09 | 2014-01-30 | Northwestern University | Particles for detecting intracellular targets |
US8440881B2 (en) | 2007-02-28 | 2013-05-14 | Cropdesign N.V. | Plants having enhanced yield-related traits and a method for making the same |
CA2681661C (en) | 2007-03-23 | 2015-11-24 | New York University | Methods of increasing nitrogen-assimilation capacity in transgenic plants expressing cca1 and glk1 |
AU2008237319B2 (en) | 2007-04-04 | 2014-11-13 | Basf Plant Science Gmbh | AHAS mutants |
US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
ES2516827T3 (es) * | 2007-04-23 | 2014-10-31 | Deliversir Ltd | Un sistema para entregar agentes terapéuticos a células vivas y núcleos de células |
US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
EP2228386B1 (en) | 2007-05-03 | 2015-03-18 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
AR067318A1 (es) | 2007-05-22 | 2009-10-07 | Basf Plant Science Gmbh | Plantas con mayor tolerancia y/o resistencia aumentada al estres ambiental y mayor produccion de biomasa |
DE112008001453T5 (de) | 2007-05-22 | 2010-04-29 | Basf Plant Science Gmbh | Pflanzenzellen und Pflanzen mit erhöhter Toleranz und/oder Resistenz gegenüber Umweltstress und erhöhter Biomasseproduktion-KO |
CN101688214A (zh) | 2007-05-23 | 2010-03-31 | 克罗普迪塞恩股份有限公司 | 具有增强的产量相关性状的植物和用于产生该植物的方法 |
CN101679493A (zh) | 2007-05-25 | 2010-03-24 | 克罗普迪塞恩股份有限公司 | 在植物中通过调节玉米alfin的产量增强 |
DK2170917T3 (da) | 2007-05-30 | 2012-10-08 | Isis Pharmaceuticals Inc | N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro |
EP2826863B1 (en) | 2007-05-30 | 2017-08-23 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
WO2009003977A2 (en) | 2007-06-29 | 2009-01-08 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
WO2009006478A2 (en) | 2007-07-05 | 2009-01-08 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
DE112008001879T5 (de) | 2007-07-20 | 2010-07-29 | Basf Plant Science Gmbh | Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu irer Herstellung |
EP2183372A2 (en) | 2007-07-31 | 2010-05-12 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
AR067748A1 (es) | 2007-07-31 | 2009-10-21 | Basf Plant Science Gmbh | Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas |
WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
EP2188298B1 (en) | 2007-08-15 | 2013-09-18 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
MX2010002753A (es) | 2007-09-14 | 2010-03-30 | Basf Plant Science Gmbh | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas. |
AU2008300579B2 (en) | 2007-09-18 | 2014-11-13 | Basf Plant Science Gmbh | Plants with increased yield |
WO2009039442A1 (en) | 2007-09-21 | 2009-03-26 | California Institute Of Technology | Nfia in glial fate determination, glioma therapy and astrocytoma treatment |
CN101868544B (zh) | 2007-09-21 | 2016-04-06 | 巴斯夫植物科学有限公司 | 具有提高的产量相关性状的植物和用于制备该植物的方法 |
US8809059B2 (en) | 2007-09-21 | 2014-08-19 | Basf Plant Science Gmbh | Plants with increased yield |
CN102405846A (zh) * | 2007-10-05 | 2012-04-11 | 因斯玛公司 | 芸苔属中突变的乙酰羟酸合酶基因 |
WO2009045536A2 (en) * | 2007-10-05 | 2009-04-09 | The University Of North Carolina At Chapel Hill | Receptor targeted oligonucleotides |
US20110071047A1 (en) * | 2007-10-27 | 2011-03-24 | O.D. 260 Inc. | Promoter detection and analysis |
US20090111099A1 (en) * | 2007-10-27 | 2009-04-30 | Yongsheng Ma | Promoter Detection and Analysis |
BRPI0818482A2 (pt) | 2007-10-29 | 2014-10-07 | Basf Plant Science Gmbh | Método para intensificar as características relacionadas ao redimento, constructo, uso de um constructo, planta , parte de planta ou célula de planta, método para a produção de uma planta transgênica, planta transgênica, partes colhíves de uma planta, produtos, e, uso de um ácido nucleico |
EP2220231B1 (en) | 2007-11-12 | 2017-10-11 | North Carolina State University | Alteration of tobacco alkaloid content through modification of specific cytochrome p450 genes |
EP2219680A2 (en) | 2007-11-13 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
MX2010005565A (es) | 2007-11-20 | 2010-06-11 | Pioneer Hi Bred Int | Genes de señalizacion de etileno en maiz y su modulacion para mejor tolerancia al estres en plantas. |
USRE47320E1 (en) | 2007-11-20 | 2019-03-26 | Ionis Pharmaceuticals, Inc. | Modulation of CD40 expression |
WO2009067647A1 (en) * | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
CN103773795A (zh) | 2007-11-22 | 2014-05-07 | 克罗普迪塞恩股份有限公司 | 具有增强的产量相关性状的植物及其生产方法 |
EP2574621A1 (en) | 2007-11-26 | 2013-04-03 | BASF Plant Science GmbH | Plants having enhanced yield-related traits and a method for making the same |
AR069893A1 (es) | 2007-12-19 | 2010-02-24 | Basf Plant Science Gmbh | Plantas con mayor rendimiento y/o mayor tolerancia al estres ambiental (iy-bm) |
DE112008003316T5 (de) | 2007-12-20 | 2011-05-05 | Basf Plant Science Gmbh | Pflanzen mit gesteigerten ertragsbezogenen Eigenschaften und Verfahren zur Herstellung derselben |
EP2240587A2 (en) | 2007-12-21 | 2010-10-20 | BASF Plant Science GmbH | Plants with increased yield (ko nue) |
PL2234994T3 (pl) * | 2007-12-27 | 2018-02-28 | Cibus Europe B.V. | Mieszanki estrów butylowych kwasów tłuszczowych |
AU2009207611A1 (en) | 2008-01-25 | 2009-07-30 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
WO2009095881A2 (en) | 2008-01-31 | 2009-08-06 | National Institute For Biological Sciences | Plants having altered growth and/or development and a method for making the same |
EP2265627A2 (en) | 2008-02-07 | 2010-12-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
US20110010800A1 (en) | 2008-02-27 | 2011-01-13 | Basf Plant Science Gmbh | Plants with increased yield |
EP2282744B1 (en) | 2008-03-21 | 2018-01-17 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucleosides and methods for their use |
EP2285819B1 (en) | 2008-04-04 | 2013-10-16 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
DE112009000705T5 (de) | 2008-04-16 | 2011-06-16 | Basf Plant Science Gmbh | Pflanzen mit gesteigerten ertragsbezogenen Eigenschaften und Verfahren zur Herstellung derselben |
DE112009000934T5 (de) | 2008-05-05 | 2011-07-14 | BASF Plant Science GmbH, 67063 | Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu ihrer Herstellung |
CA2725175A1 (en) | 2008-05-23 | 2009-11-26 | Cibus Oils, Llc | Production of squalene using yeast |
CN103834683A (zh) | 2008-06-20 | 2014-06-04 | 巴斯夫植物科学有限公司 | 具有增强的产量相关性状的植物和产生所述植物的方法 |
US8779237B2 (en) | 2008-06-26 | 2014-07-15 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EA201100146A1 (ru) | 2008-07-04 | 2011-12-30 | Басф Плант Сайенс Гмбх | Растения, имеющие улучшенные характеристики урожайности, и способ их получения |
WO2010007035A1 (en) | 2008-07-17 | 2010-01-21 | Basf Plant Science Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP2669379A3 (en) | 2008-07-31 | 2014-03-19 | BASF Plant Science GmbH | Plants having modified growth characteristics and a method for making the same |
AU2009279682B2 (en) | 2008-08-04 | 2015-01-22 | University Of Miami | STING (stimulator of interferon genes), a regulator of innate immune responses |
CN103923892A (zh) | 2008-08-19 | 2014-07-16 | 巴斯夫植物科学有限公司 | 通过在植物或其部分中提高或产生一种或更多活性具有提高产量的植物 |
US20110145949A1 (en) | 2008-08-20 | 2011-06-16 | Basf Plant Science Gmbh | Plants Having Enhanced Yield-Related Traits and a Method for Making the Same |
CN103429270B (zh) | 2008-08-25 | 2016-11-23 | 埃克斯雷德制药有限公司 | 阻止结缔组织生长因子的反义核苷酸及其用途 |
CN102159711B (zh) | 2008-09-11 | 2014-01-29 | 凯津公司 | 形成鉴别标记物的方法 |
BRPI0919153A2 (pt) | 2008-09-23 | 2019-05-07 | Basf Plant Science Gmbh | método para produzir uma planta com rendimento aumentado, molécula de ácido nucleico, construto de ácido nucleico, vetor, processo para produzir um polipeptídeo, poliptídeo, anticorpo, núcleo de célula de planta, célula de planta, tecido de planta, material de propagação, pólen, progênie, material coletado, ou uma planta, ou uma parte da planta, planta transgênica, processo para identificar um composto, método para a produção de uma composição agrícola, composição, uso de ácido nucleico, e, método para a identificação de uma planta com um rendimento aumentado, e para aumentar o rendimento de uma população de plantas |
EP2361256B1 (en) | 2008-09-24 | 2013-04-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
DE112009002224T5 (de) | 2008-09-24 | 2012-01-19 | Basf Plant Science Gmbh | Pflanzen mit gesteigerten ertragsbezogenen Eigenschaften und Verfahren zu deren Herstellung |
DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
PL2733212T3 (pl) | 2008-09-26 | 2019-06-28 | Basf Agrochemical Products, B.V. | Mutanty ahas odporne na herbicyd i sposoby ich zastosowania |
EP2379084B1 (en) | 2008-10-15 | 2017-11-22 | Ionis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
BRPI0919759A2 (pt) * | 2008-10-20 | 2017-03-21 | Moerae Matrix Inc | polipeptídeos para tratamento e prevenção de adesões |
WO2010046422A2 (en) | 2008-10-22 | 2010-04-29 | Basf Se | Use of auxin type herbicides on cultivated plants |
AR075465A1 (es) | 2008-10-22 | 2011-04-06 | Basf Se | Uso de herbicidas de sulfonilurea en plantas cultivadas |
AU2009306575B2 (en) | 2008-10-23 | 2016-04-14 | Basf Plant Science Gmbh | Plants with increased yield (NUE) |
DE112009002342T5 (de) | 2008-10-23 | 2012-06-14 | Basf Plant Science Gmbh | Verfahren zum Herstellen einer transgenen Zelle mit erhöhtem Gehalt an gamma-Aminobuttersäure (GABA) |
WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
CN102264374B (zh) | 2008-10-24 | 2015-01-07 | Isis制药公司 | 5′和2′双取代的核苷和由其制备的低聚化合物 |
MX2011003616A (es) | 2008-10-30 | 2011-08-15 | Pioneer Hi Bred Int | Manipulacion de glutamina sintetasas (gs) para mejorar la eficiencia de uso de nitrogeno y rendimiento de grano en plantas superiores. |
EP2184351A1 (en) | 2008-10-30 | 2010-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Polynucleotides encoding caryophyllene synthase and uses thereof |
DE112009002731T5 (de) | 2008-11-12 | 2013-05-08 | Basf Plant Science Gmbh | Pflanzen mit gesteigerter abiotischer Stresstoleranz und/oder gesteigerten ertragsbezogenen Eigenschaften und Verfahren zur Herstellung derselben |
WO2010054513A1 (en) | 2008-11-14 | 2010-05-20 | Fujian Fuda Biotech Co. Ltd. | A thermotolerant non-k12 escherichia coli phytase and its production |
EP2365803B1 (en) | 2008-11-24 | 2017-11-01 | Northwestern University | Polyvalent rna-nanoparticle compositions |
BRPI0922553A2 (pt) | 2008-12-03 | 2013-05-07 | Basf Plant Science Gmbh | mÉtodo para aumentar a tolerÂncia a estresse abiàtico e/ou para aumentar uma caracterÍstica relacionada ao rendimento em uma planta, construto, planta, cÉlula de planta ou parte da mesma, incluindo sementes, partes cultivÁveis da dita planta, produtos derivados de dita planta e/ou de ditas partes cultivÁveis, mÉtodo para a produÇço de plantas transgÊnicas, uso de um construto ou de um Ácido nucleico, molÉcula de Ácido nucleico isolada, e, polipeptÍdeo isolado |
KR101749352B1 (ko) | 2008-12-04 | 2017-06-20 | 큐알엔에이, 인크. | Sirt1에 대한 천연 안티센스 전사체의 억제에 의해 sirt1 관련된 질환의 치료 |
MX2011005910A (es) | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina. |
MX358603B (es) | 2008-12-04 | 2018-08-28 | Curna Inc | Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen. |
WO2010065867A1 (en) | 2008-12-04 | 2010-06-10 | Pioneer Hi-Bred International, Inc. | Methods and compositions for enhanced yield by targeted expression of knotted1 |
AU2009324661A1 (en) | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
ES2435572T3 (es) | 2008-12-12 | 2013-12-20 | Basf Plant Science Gmbh | Desaturasas y proceso para la producción de ácidos grasos poliinsaturados en organismos transgénicos |
DE112009003749T5 (de) | 2008-12-17 | 2012-11-15 | Basf Plant Science Gmbh | Pflanzen mit gesteigerten ertragsbezogenen Eigenschaften und/oder gesteigerter abiotischerStresstoleranz und Verfahren zur Herstellung derselben |
CA2746508A1 (en) | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
EP2204086A1 (en) | 2009-01-02 | 2010-07-07 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK) | Six row-type barley |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
WO2010083328A2 (en) | 2009-01-14 | 2010-07-22 | The Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
EA201170947A1 (ru) | 2009-01-28 | 2012-07-30 | Басф Плант Сайенс Компани Гмбх | Растения, имеющие улучшенные характеристики урожайности, и способ их получения |
US8536320B2 (en) | 2009-02-06 | 2013-09-17 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
US20120021515A1 (en) | 2009-02-06 | 2012-01-26 | Swayze Eric E | Oligomeric compounds and methods |
ES2762610T3 (es) | 2009-02-12 | 2020-05-25 | Curna Inc | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF |
JP6066035B2 (ja) | 2009-02-12 | 2017-01-25 | クルナ・インコーポレーテッド | グリア細胞由来神経栄養因子(gdnf)関連疾病の、gdnfに対する天然アンチセンス転写物の抑制による治療 |
CN102482333A (zh) | 2009-02-25 | 2012-05-30 | 巴斯夫植物科学有限公司 | 具有增强的产量相关性状的植物及其制备方法 |
WO2010101818A1 (en) | 2009-03-02 | 2010-09-10 | Pioneer Hi-Bred International, Inc. | Nac transcriptional activators involved in abiotic stress tolerance |
EP2963116B1 (en) | 2009-03-04 | 2020-11-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 |
ES2656290T3 (es) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2 |
JP5904935B2 (ja) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療 |
BRPI1014658A2 (pt) | 2009-04-14 | 2019-09-24 | Pioneer Hi Bred Int | "método para aperfeiçoar a tolerância ao estresse de intrôgenio em uma planta, método para aperfeiçoar a tolerância ao estresse de nitrogênio sob condições com pouco nitrogênio, cassete de expressão, construto, célula vegetal, planta e método de inibição da produção de etileno em uma planta." |
US20120036594A1 (en) | 2009-04-21 | 2012-02-09 | Basf Plant Science Company Gmbh | RNA-Mediated Induction of Gene Expression in Plants |
US20120047602A1 (en) | 2009-04-21 | 2012-02-23 | Basf Plant Science Company Gmbh | RNA-Mediated Induction of Gene Expression in Plants |
EP3524275A1 (en) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Innate immune supression enables repeated delivery of long rna molecules |
AU2010243730B2 (en) | 2009-04-29 | 2016-04-21 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
CN102459613A (zh) | 2009-04-29 | 2012-05-16 | 巴斯夫植物科学有限公司 | 具有增强的产量相关性状的植物及其制备方法 |
CA2760589C (en) | 2009-05-01 | 2019-08-20 | Joseph Collard | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
WO2010129501A1 (en) | 2009-05-04 | 2010-11-11 | Pioneer Hi-Bred International, Inc. | Yield enhancement in plants by modulation of ap2 transcription factor |
CN102803492B (zh) | 2009-05-06 | 2016-06-29 | 库尔纳公司 | 通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病 |
KR101835889B1 (ko) | 2009-05-06 | 2018-03-08 | 큐알엔에이, 인크. | 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료 |
AU2010244546A1 (en) | 2009-05-06 | 2011-12-01 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and/or enhanced abiotic stress tolerance and a method for making the same |
NO2432881T3 (ja) | 2009-05-18 | 2018-04-14 | ||
JP2012527248A (ja) | 2009-05-22 | 2012-11-08 | クルナ・インコーポレーテッド | 転写因子e3(tfe3)に対する天然アンチセンス転写物の阻害によるtfe3およびインスリン受容体基質2(irs2)関連疾患の処置 |
ES2618576T3 (es) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico |
US20120171170A1 (en) | 2009-06-16 | 2012-07-05 | Opko Curna, Llc | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
US8951981B2 (en) | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
WO2011006717A2 (en) | 2009-06-19 | 2011-01-20 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
CN102597238B (zh) | 2009-06-24 | 2016-06-29 | 库尔纳公司 | 通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病 |
US8921330B2 (en) | 2009-06-26 | 2014-12-30 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
EP2449099A2 (en) | 2009-06-30 | 2012-05-09 | E. I. du Pont de Nemours and Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding cytosolic pyrophosphatase |
ATE550350T1 (de) | 2009-07-10 | 2012-04-15 | Univ Berlin Freie | Rock2 und rock3, zwei neue gain-of-function- varianten der cytokininrezeptoren ahk2 und ahk3 |
EP2275564A1 (en) | 2009-07-17 | 2011-01-19 | Freie Universität Berlin | Means and method for the production of transgenic plants that are resistant to clubroot |
US20120117867A1 (en) | 2009-07-23 | 2012-05-17 | Basf Plant Science Company Gmbh | Plants with Increased Yield |
EA201200177A1 (ru) | 2009-07-24 | 2012-06-29 | Пайонир Хай-Бред Интернэшнл, Инк. | Применение связок компонентов домена димеризации для регулирования архитектуры растения |
US9890195B2 (en) * | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
US9234199B2 (en) | 2009-08-05 | 2016-01-12 | Curna, Inc. | Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) |
WO2011017492A2 (en) | 2009-08-05 | 2011-02-10 | Pioneer Hi-Bred International, Inc. | Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants |
US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
GB0914012D0 (en) | 2009-08-11 | 2009-09-16 | Plant Bioscience Ltd | Stress tolerant plants |
ES2542536T3 (es) | 2009-08-19 | 2015-08-06 | Basf Plant Science Company Gmbh | Plantas que tienen rasgos potenciados relacionados con el rendimiento y un procedimiento de producción de las mismas |
US20110061132A1 (en) | 2009-08-20 | 2011-03-10 | Pioneer Hi-Bred International, Inc. | Functional expression of yeast nitrate transporter (ynt1) in maize to improve nitrate uptake |
US9023822B2 (en) | 2009-08-25 | 2015-05-05 | Curna, Inc. | Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP |
EP3121283B1 (en) | 2009-08-31 | 2018-05-02 | BASF Plant Science Company GmbH | Regulatory nucleic acid molecules for enhancing seed-specific gene expression in plants promoting enhanced polyunsaturated fatty acid synthesis |
RU2012112347A (ru) | 2009-08-31 | 2013-10-10 | Басф Плант Сайенс Компани Гмбх | Регуляторные молекулы нуклеиновых кислот для усиления конститутивной генной экспрессии в растениях |
RU2559534C2 (ru) | 2009-08-31 | 2015-08-10 | Басф Плант Сайенс Компани Гмбх | Регуляторные молекулы нуклеиновых кислот для усиления семя-специфичной и/или семя-предпочтительной генной экспрессии в растениях |
JP5887270B2 (ja) | 2009-09-02 | 2016-03-16 | ジェネンテック, インコーポレイテッド | 突然変異体smoothenedおよびその使用方法 |
CA2772983A1 (en) | 2009-09-25 | 2011-03-31 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
AR080340A1 (es) | 2009-09-25 | 2012-04-04 | Crop Functional Genomics Ct | Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas mediante la modulacion de la expresion de sgt-1, clcpkg o un polipeptido tipo hd-hidrolasa |
CA2775093A1 (en) | 2009-10-02 | 2011-04-07 | Pioneer Hi-Bred International, Inc. | Down-regulation of acc synthase for improved plant performance |
JP5819308B2 (ja) | 2009-10-22 | 2015-11-24 | ジェネンテック, インコーポレイテッド | マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物 |
CN102666858A (zh) | 2009-10-22 | 2012-09-12 | 巴斯夫植物科学有限公司 | 具有增强的产量相关性状的植物和用于产生该植物的方法 |
EP2494075B1 (en) | 2009-10-30 | 2018-04-04 | Northwestern University | Templated nanoconjugates |
AR078829A1 (es) | 2009-10-30 | 2011-12-07 | Du Pont | Plantas y semillas con niveles alterados de compuesto de almacenamiento, construcciones relacionadas y metodos relacionados con genes que codifican proteinas similares a las aldolasas bacterianas de la clase ii del acido 2,4- dihidroxi-hept-2-eno-1,7-dioico |
WO2011058029A1 (en) | 2009-11-13 | 2011-05-19 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
BR112012011381B8 (pt) | 2009-11-13 | 2021-05-25 | Avi Biopharma Inc | oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo |
AU2010320547B2 (en) | 2009-11-17 | 2016-06-09 | Basf Plant Science Company Gmbh | Plants with increased yield |
DK3219815T3 (da) | 2009-11-23 | 2019-12-16 | Cibus Europe Bv | Fremgangsmåder og sammensætninger til at fremstille squalen under anvendelse af gær |
EP3002297B1 (en) | 2009-11-30 | 2020-04-08 | F. Hoffmann-La Roche AG | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211) |
ES2661813T3 (es) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1 |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
WO2011090690A1 (en) | 2009-12-28 | 2011-07-28 | Pioneer Hi-Bred International, Inc. | Sorghum fertility restorer genotypes and methods of marker-assisted selection |
JP5993744B2 (ja) | 2009-12-29 | 2016-09-14 | カッパーアールエヌエー,インコーポレイテッド | 核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療 |
CA2785177C (en) | 2009-12-29 | 2019-09-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
WO2011082304A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
RU2611187C2 (ru) | 2010-01-04 | 2017-02-21 | Курна, Инк. | Лечение заболеваний, связанных с интерферон-регуляторным фактором 8 (irf8), путем ингибирования природного антисмыслового транскрипта к irf8 |
CA2786056C (en) | 2010-01-06 | 2023-03-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
WO2011085062A1 (en) | 2010-01-06 | 2011-07-14 | Pioneer Hi-Bred International, Inc. | Identification of diurnal rhythms in photosynthetic and non-photosynthetic tissues from zea mays and use in improving crop plants |
EP2524039B1 (en) | 2010-01-11 | 2017-11-29 | CuRNA, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
US20110236325A1 (en) | 2010-01-21 | 2011-09-29 | NellOne Therapeutics, Inc. | Methods to treat or prevent a skin condition using a nell1 peptide |
CN102782135A (zh) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | 通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病 |
AR080021A1 (es) | 2010-01-26 | 2012-03-07 | Pioneer Hi Bred Int | Tolerancia a los herbicidas inhibidores de hppd (hidrofenil piruvato dioxigenasa) |
US8962586B2 (en) | 2010-02-22 | 2015-02-24 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1 |
CN102985113B (zh) | 2010-02-23 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 用于肿瘤诊断和治疗的组合物和方法 |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
AU2011219927A1 (en) | 2010-02-24 | 2012-08-23 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
WO2011104128A2 (en) | 2010-02-24 | 2011-09-01 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EP2361985A1 (en) | 2010-02-26 | 2011-08-31 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP2361927A1 (en) | 2010-02-26 | 2011-08-31 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
EP2542682A2 (en) | 2010-03-03 | 2013-01-09 | E.I. Du Pont De Nemours And Company | Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding oxidoreductase motif polypeptides |
GB201003702D0 (en) | 2010-03-05 | 2010-04-21 | Univ Warwick | Molecular engineering of a floral inducer for crop improvement |
WO2011112732A2 (en) | 2010-03-12 | 2011-09-15 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
US9068185B2 (en) | 2010-03-12 | 2015-06-30 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
US9193752B2 (en) | 2010-03-17 | 2015-11-24 | Isis Pharmaceuticals, Inc. | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
BR112012022880A2 (pt) | 2010-03-18 | 2015-09-15 | Basf Plant Science Co Gmbh | métodos para aumentar o rendimento e/ou traços relacionados ao rendimento em plantas em relação a plantas de controle, para a produção de uma planta transgênica e para a produção de um produto, planta, construção, uso de uma construção, planta transgênica, partes colhíveis de uma planta, produtos derivados de uma planta e uso de um ácido nucleíco |
MX2012010600A (es) | 2010-03-18 | 2012-10-05 | Basf Plant Science Co Gmbh | Plantas que tienen mejores rasgos relacionados con el redimiento y un metodo para producirlas. |
US20130019347A1 (en) | 2010-03-19 | 2013-01-17 | Basf Plant Science Company Gmbh | Plants having enhanced yield-related traits and a method for making the same |
EA201290937A1 (ru) | 2010-03-19 | 2013-06-28 | Басф Плант Сайенс Компани Гмбх | Растения с улучшенными характеристиками урожайности и способ их получения |
EP2371845A1 (en) | 2010-03-22 | 2011-10-05 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
CN102858979B (zh) | 2010-04-09 | 2018-01-26 | 库尔纳公司 | 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病 |
EP2385129A1 (en) | 2010-05-03 | 2011-11-09 | BASF Plant Science Company GmbH | Enhanced methods for gene regulation in plants |
EP2563380B1 (en) | 2010-04-26 | 2018-05-30 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
AU2011248614B2 (en) | 2010-04-27 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
EP3091027B1 (en) | 2010-04-28 | 2018-01-17 | Ionis Pharmaceuticals, Inc. | 5' modified nucleosides and oligomeric compounds prepared therefrom |
AU2011248489B2 (en) | 2010-04-28 | 2016-10-06 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases |
CN103154014B (zh) | 2010-04-28 | 2015-03-25 | Isis制药公司 | 修饰核苷、其类似物以及由它们制备的寡聚化合物 |
CN103097523B (zh) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
ES2625689T3 (es) | 2010-04-29 | 2017-07-20 | Ionis Pharmaceuticals, Inc. | Modulación de la expresión de transtiretina |
AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
JP6008840B2 (ja) | 2010-05-03 | 2016-10-19 | エータイアー ファーマ, インコーポレイテッド | フェニルアラニルαtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CA2797277C (en) | 2010-05-03 | 2021-02-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases |
MA34291B1 (fr) | 2010-05-03 | 2013-06-01 | Genentech Inc | Compositions et méthodes de diagnostic et de traitement d'une tumeur |
RU2693462C2 (ru) | 2010-05-03 | 2019-07-03 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
AU2011248230B2 (en) | 2010-05-03 | 2016-10-06 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
WO2011145015A1 (en) | 2010-05-04 | 2011-11-24 | Basf Se | Plants having increased tolerance to herbicides |
CN102985103A (zh) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现 |
MX2012012672A (es) | 2010-05-06 | 2012-12-17 | Du Pont | Gen y proteina acc sintasa 3 de maiz y sus usos. |
GB201007834D0 (en) | 2010-05-11 | 2010-06-23 | Vib Vzw | Growth promoting fusion proteins |
ES2705236T3 (es) | 2010-05-12 | 2019-03-22 | Univ Columbia | Procedimientos para producir células enteroendocrinas que producen y secretan insulina |
US9238042B2 (en) | 2010-05-13 | 2016-01-19 | Sarepta Therapeutics, Inc. | Antisense modulation of interleukins 17 and 23 signaling |
EP2568996B1 (en) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制par4天然反股轉錄本治療par4相關疾病 |
JP6027965B2 (ja) | 2010-05-17 | 2016-11-16 | エータイアー ファーマ, インコーポレイテッド | ロイシルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
ES2664572T3 (es) | 2010-05-26 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el homólogo atonal 1 (ATOH1) mediante inhibición del transcrito antisentido natural a ATOH1 |
AU2011258106B2 (en) | 2010-05-27 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
US8957200B2 (en) | 2010-06-07 | 2015-02-17 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2011159758A2 (en) | 2010-06-15 | 2011-12-22 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
BR112012032996A2 (pt) | 2010-06-24 | 2019-09-24 | Basf Plant Science Co Gmbh | método para acentuar os traços relacionados a rendimento em plantas em relação a plantas de controle, planta, construto, uso de contruto, método para a produção de uma planta transgênica, planta transgênica, partes colhíveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco, ácido nucleíco isolado, polipeptídeo isolado e molécula nucleíca isolada |
DE112011102151T5 (de) | 2010-06-25 | 2013-07-11 | Basf Plant Science Company Gmbh | Pflanzen mit gesteigerten Ertragsmerkmalen und Verfahren zu deren Herstellung |
CN103080320A (zh) | 2010-07-01 | 2013-05-01 | 纳幕尔杜邦公司 | 涉及编码pae以及pae样多肽的基因并具有改变的贮藏化合物水平的植物种子、相关的构建体和的方法 |
CN103124738B (zh) | 2010-07-08 | 2016-08-17 | 拜尔作物科学公司 | 芥子油苷转运蛋白及其用途 |
EP2593125B1 (en) | 2010-07-12 | 2017-11-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
JP5998131B2 (ja) | 2010-07-14 | 2016-09-28 | カッパーアールエヌエー,インコーポレイテッド | Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療 |
EA201390111A1 (ru) | 2010-07-16 | 2013-06-28 | Басф Плант Сайенс Компани Гмбх | Растения с улучшенными характеристиками урожайности и способ их получения |
US20120122223A1 (en) | 2010-08-03 | 2012-05-17 | Cibus Us Llc | Mutated protoporphyrinogen ix oxidase (ppx) genes |
UA112969C2 (uk) | 2010-08-03 | 2016-11-25 | Сібас Юс Ллс | Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх) |
AU2011289274B2 (en) | 2010-08-13 | 2015-02-26 | Pioneer Hi-Bred International, Inc. | Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity |
MX2013002137A (es) | 2010-08-24 | 2013-05-17 | Basf Plant Science Co Gmbh | Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para prepararlas. |
US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
EP2426204A1 (en) | 2010-09-02 | 2012-03-07 | Ludwig-Maximilians-Universität München | Spontaneous nodule organogenesis in plants |
WO2012028673A1 (en) | 2010-09-02 | 2012-03-08 | Ludwig-Maximilians-Universitaet Muenchen | Spontaneous organogenesis in plants |
CA2813738A1 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
RU2624048C2 (ru) | 2010-10-06 | 2017-06-30 | Курна, Инк. | Лечение заболеваний, связанных с геном сиалидазы 4 (neu4), путем ингибирования природного антисмыслового транскрипта гена neu4 |
EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
JP6049623B2 (ja) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー,インコーポレイテッド | α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療 |
KR101913232B1 (ko) | 2010-10-27 | 2018-10-30 | 큐알엔에이, 인크. | 인터페론-관련된 발달성 조절물질 1 (ifrd1)에 대한 자연 안티센스 전사체의 저해에 의한 ifrd1 관련된 질환의 치료 |
BR112013011523A2 (pt) | 2010-11-10 | 2019-09-24 | Basf Plant Science Co Gmbh | método, planta, construto, uso, planta transgênica, partes colhíveis de uma planta, produtos e partes colhíveis de uma planta |
US9328346B2 (en) | 2010-11-12 | 2016-05-03 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
US8609621B2 (en) | 2010-11-15 | 2013-12-17 | E I Du Pont De Nemours And Company | Acid-cleavable linkers exhibiting altered rates of acid hydrolysis |
CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
ES2657590T3 (es) | 2010-11-23 | 2018-03-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog |
US9834778B2 (en) | 2010-12-06 | 2017-12-05 | Basf Plant Science Company Gmbh | Synthetic arcelin-5 promoter and methods of use thereof |
EA029356B1 (ru) | 2010-12-16 | 2018-03-30 | Басф Агро Б.В. | Растения с повышенной устойчивостью к гербицидам |
EA201390918A1 (ru) | 2010-12-22 | 2013-11-29 | Пайонир Хай-Бред Интернэшнл, Инк. | Qtl, ассоциированные с полевой устойчивостью всего растения к sclerotinia, и способы ее идентификации |
US9045749B2 (en) | 2011-01-14 | 2015-06-02 | The General Hospital Corporation | Methods targeting miR-128 for regulating cholesterol/lipid metabolism |
CN103429745A (zh) | 2011-01-20 | 2013-12-04 | 巴斯夫植物科学有限公司 | 具有增强的产量相关性状的植物和用于制备该植物的方法 |
US9688719B2 (en) | 2011-01-27 | 2017-06-27 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
US9243034B2 (en) | 2011-01-27 | 2016-01-26 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
CN107603960A (zh) | 2011-02-01 | 2018-01-19 | 科罗拉多小麦研究基金会公司 | 乙酰辅酶a羧化酶除草剂抗性植物 |
CN103391777A (zh) | 2011-02-02 | 2013-11-13 | 普林斯顿大学理事会 | 作为病毒产生调节剂的去乙酰化酶调节剂 |
TWI593416B (zh) | 2011-02-02 | 2017-08-01 | 艾克厘德製藥公司 | 利用針對結締組織生長因子(ctgf)目標之反義化合物治療瘢痕或肥厚性疤痕之方法 |
US9273336B2 (en) | 2011-02-21 | 2016-03-01 | E. I. Du Pont De Nemours And Company | Recombinant host cells having an increase in buoyant density |
AR085394A1 (es) | 2011-02-25 | 2013-09-25 | Univ Nac De La Plata Unlp | Proteasa de plantas |
DE112012001017T5 (de) | 2011-02-28 | 2013-12-19 | Basf Plant Science Company Gmbh | Pflanzen mit gesteigerten Ertragsmerkmalen und Verfahren zu deren Herstellung |
EP2681325A4 (en) | 2011-02-28 | 2014-10-22 | Basf Plant Science Co Gmbh | PLANTS WITH IMPROVED EFFICIENCY AND MANUFACTURING METHOD THEREFOR |
MX2013009997A (es) | 2011-03-01 | 2014-07-09 | Basf Plant Science Co Gmbh | Plantas que tienen rasgos relacionados con rendimiento mejorado y metodos para producir los mismos. |
MX359516B (es) | 2011-04-12 | 2018-10-01 | Moerae Matrix Inc | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. |
US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
EP2794643A1 (en) | 2011-04-29 | 2014-10-29 | Pioneer Hi-Bred International Inc. | Down-regulation of a homeodomain-leucine zipper i-class homeobox gene for improved plant performance |
CA2834183A1 (en) | 2011-05-19 | 2012-11-22 | Enrique ROJO DE LA VIESCA | Process for modifying the architecture and improving the yield of crop plants |
WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
ES2653247T3 (es) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la frataxina (FXN) mediante inhibición del transcrito antisentido natural al gen FXN |
US20140216118A1 (en) | 2011-06-14 | 2014-08-07 | Synthon Biopharmaceuticals B.V. | Compositions and Methods for Making and Biocontaining Auxotrophic Transgenic Plants |
AR087167A1 (es) | 2011-07-12 | 2014-02-26 | Two Blades Foundation | Genes de resistencia al tizon tardio |
WO2013012643A1 (en) | 2011-07-15 | 2013-01-24 | Syngenta Participations Ag | Polynucleotides encoding trehalose-6-phosphate phosphatase and methods of use thereof |
MX347810B (es) | 2011-07-15 | 2017-05-15 | Syngenta Participations Ag | Métodos para mejorar el rendimiento y la tolerancia al estrés en una planta. |
EP2739737A4 (en) | 2011-08-01 | 2015-08-26 | Basf Plant Science Co Gmbh | METHOD OF IDENTIFYING AND INSULATING CLOSURE SEQUENCES FOR IMPROVED TRANSCRIPTION |
WO2013040499A1 (en) | 2011-09-14 | 2013-03-21 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
CA2848753C (en) | 2011-09-14 | 2022-07-26 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
WO2013055865A1 (en) | 2011-10-11 | 2013-04-18 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
CA2853449A1 (en) | 2011-10-25 | 2013-05-02 | Pioneer Hi-Bred International, Inc. | Methods to alter plant cell wall composition for improved biofuel production and silage digestibility |
CN104093842B (zh) | 2011-10-31 | 2016-12-07 | 先锋国际良种公司 | 改善植物耐旱性、氮利用效率和产量 |
EP2790736B1 (en) | 2011-12-12 | 2018-01-31 | Oncoimmunin, Inc. | In vivo delivery of oligonucleotides |
CN104204193B (zh) | 2012-02-13 | 2016-10-26 | 加米达细胞有限公司 | 间充质干细胞的培养 |
WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
WO2013138309A1 (en) | 2012-03-13 | 2013-09-19 | Pioneer Hi-Bred International, Inc. | Genetic reduction of male fertility in plants |
CA2867385A1 (en) | 2012-03-13 | 2013-09-19 | Pioneer Hi-Bred International, Inc. | Genetic reduction of male fertility in plants |
EP2825648B1 (en) | 2012-03-15 | 2018-09-05 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
AU2013248981B2 (en) | 2012-04-20 | 2018-11-29 | Aptamir Therapeutics, Inc. | Mirna modulators of thermogenesis |
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
EA201492123A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии семейства генов smn |
JP2015518714A (ja) | 2012-05-16 | 2015-07-06 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
US10045499B2 (en) | 2012-05-24 | 2018-08-14 | Iowa State University Research Foundation, Inc. | Arabidopsis nonhost resistance gene(s) and use thereof to engineer disease resistant plants |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
AR091489A1 (es) | 2012-06-19 | 2015-02-11 | Basf Se | Plantas que tienen una mayor tolerancia a herbicidas inhibidores de la protoporfirinogeno oxidasa (ppo) |
EP2677035A1 (en) | 2012-06-22 | 2013-12-25 | BASF Plant Science Company GmbH | Plants having enhanced yield-related traits and a method for making the same |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
WO2014022852A1 (en) | 2012-08-03 | 2014-02-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
EP2885312A4 (en) | 2012-08-15 | 2016-01-20 | Isis Pharmaceuticals Inc | PROCESS FOR THE PREPARATION OF OLIGOMERIC COMPOUNDS USING MODIFIED STREAMING PROTOCOLS |
US10006041B2 (en) | 2012-08-16 | 2018-06-26 | Vib Vzw | Means and methods for altering the lignin pathway in plants |
WO2014037735A1 (en) | 2012-09-10 | 2014-03-13 | University Of Leicester | Atsp1, an e3 ubiquitin ligase, and its use |
US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
AU2013336237A1 (en) | 2012-10-22 | 2015-06-11 | Sabag-Rfa Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
CA2889557A1 (en) | 2012-11-20 | 2014-05-30 | Pioneer Hi-Bred International., Inc. | Engineering plants for efficient uptake and utilization of urea to improve crop production |
WO2014100525A2 (en) | 2012-12-21 | 2014-06-26 | Pioneer Hi-Bred International, Inc. | Compositions and methods for auxin-analog conjugation |
EP2754715A1 (en) | 2013-01-11 | 2014-07-16 | Consejo Superior De Investigaciones Científicas (CSIC) | Stress tolerant plants |
CA2897482A1 (en) | 2013-01-29 | 2014-08-07 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing hcp7 |
US10231397B2 (en) | 2013-01-29 | 2019-03-19 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing EIN2 |
WO2014117990A1 (en) | 2013-01-29 | 2014-08-07 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing hcp6 |
WO2014121436A1 (en) | 2013-02-05 | 2014-08-14 | Plant Bioscience Limited | Transgenic plants |
US10465204B2 (en) | 2013-03-08 | 2019-11-05 | Basf Plant Science Company Gmbh | Fungal resistant plants expressing MybTF |
US20160002648A1 (en) | 2013-03-11 | 2016-01-07 | Mei Guo | Genes for improving nutrient uptake and abiotic stress tolerance in plants |
CN105189788B (zh) | 2013-03-12 | 2018-07-13 | 纳幕尔杜邦公司 | 用于鉴定罕见切割工程化双链断裂诱导剂的变体识别位点的方法及其组合物和用途 |
US9803214B2 (en) | 2013-03-12 | 2017-10-31 | Pioneer Hi-Bred International, Inc. | Breeding pair of wheat plants comprising an MS45 promoter inverted repeat that confers male sterility and a construct that restores fertility |
WO2014164074A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Enhanced nitrate uptake and nitrate translocation by over-expressing maize functional low-affinity nitrate transporters in transgenic maize |
WO2014164116A1 (en) | 2013-03-13 | 2014-10-09 | Pioneer Hi-Bred International, Inc. | Functional expression of bacterial major facilitator superfamily (sfm) gene in maize to improve agronomic traits and grain yield |
US20140304857A1 (en) | 2013-03-14 | 2014-10-09 | Pioneer Hi Bred International Inc | Maize stress related transcription factor 18 and uses thereof |
EP2971003A4 (en) | 2013-03-14 | 2016-11-16 | Cibus Us Llc | MUTED ALLENOXIDE SYNTHASE-2 (AOS2) GENES |
ES2921207T3 (es) * | 2013-03-15 | 2022-08-19 | Cibus Us Llc | Procedimientos y composiciones para aumentar la eficiencia de la modificación genética direccionada utilizando la reparación genética mediada por oligonucleótidos |
SI2966984T1 (sl) | 2013-03-15 | 2022-06-30 | Cibus Us Llc | Ciljana genska sprememba z oligonukleotidom posredovanega genskega popravka |
CA2903555A1 (en) | 2013-03-15 | 2014-09-18 | Pioneer Hi-Bred International, Inc. | Compositions and methods of use of acc oxidase polynucleotides and polypeptides |
US9957515B2 (en) | 2013-03-15 | 2018-05-01 | Cibus Us Llc | Methods and compositions for targeted gene modification |
WO2014152507A2 (en) | 2013-03-15 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Modulation of acc deaminase expression |
CA2904817C (en) | 2013-03-21 | 2022-10-18 | Vib Vzw | Means and methods for the reduction of photorespiration in crops |
RU2019124314A (ru) | 2013-05-01 | 2019-08-21 | Ионис Фармасьютикалз, Инк. | Сопряженные антисмысловые соединения и их применение |
ES2862125T3 (es) | 2013-06-13 | 2021-10-07 | Antisense Therapeutics Ltd | Terapia combinada para acromegalia |
EP2816115A1 (en) | 2013-06-17 | 2014-12-24 | BASF Plant Science Company GmbH | Plants having one or more enhanced yield-related traits and a method for making the same |
US9718859B2 (en) | 2013-06-24 | 2017-08-01 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
CA2917103C (en) | 2013-07-09 | 2021-01-12 | Board Of Trustees Of Michigan State University | Transgenic plants produced with a k-domain, and methods and expression cassettes related thereto |
US11459579B2 (en) | 2013-07-09 | 2022-10-04 | Board Of Trustees Of Michigan State University | Transgenic plants produced with a K-domain, and methods and expression cassettes related thereto |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
EP2896698A1 (en) | 2014-01-17 | 2015-07-22 | BASF Plant Science Company GmbH | Plants having one or more enhanced yield-related traits and a method for making the same |
WO2015116680A1 (en) | 2014-01-30 | 2015-08-06 | Two Blades Foundation | Plants with enhanced resistance to phytophthora |
SI3099333T1 (sl) | 2014-01-31 | 2021-04-30 | Temple University of the Commonwealth System of Higher Education 1938 Liacouras Walk | BAG3 kot tarča za terapijo srčne odpovedi |
EP3102197B1 (en) | 2014-02-04 | 2018-08-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
DK3116305T3 (da) | 2014-03-14 | 2024-03-04 | Cibus Us Llc | Fremgangsmåder og sammensætninger til forøgelse af effektiviteten af målrettet genmodifikation ved anvendelse af oligonukleotidmedieret genreparation |
WO2015142910A1 (en) | 2014-03-17 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
SI3119888T1 (sl) | 2014-03-19 | 2021-11-30 | Ionis Pharmaceuticals, Inc. | Sestavki za moduliranje izražanja ataksina 2 |
EP3757214B1 (en) | 2014-04-01 | 2022-06-15 | Biogen MA Inc. | Compositions for modulating sod-1 expression |
WO2015150465A2 (en) | 2014-04-03 | 2015-10-08 | Basf Se | Plants having increased tolerance to herbicides |
US10221416B2 (en) | 2014-04-24 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
EP3608406B1 (en) | 2014-05-01 | 2023-02-15 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor b expression |
WO2015171603A1 (en) | 2014-05-06 | 2015-11-12 | Two Blades Foundation | Methods for producing plants with enhanced resistance to oomycete pathogens |
EP3508198A1 (en) | 2014-06-04 | 2019-07-10 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
HRP20220379T1 (hr) | 2014-06-10 | 2022-05-27 | Erasmus University Medical Center Rotterdam | Antisense oligonukleotidi korisni u liječenju pompeove bolesti |
EP3760208B1 (en) | 2014-06-25 | 2024-05-29 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
US20170159065A1 (en) | 2014-07-08 | 2017-06-08 | Vib Vzw | Means and methods to increase plant yield |
NZ744832A (en) | 2014-07-14 | 2023-07-28 | Univ Washington State | Nanos2 knock-out that ablates germline cells |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
US10556020B2 (en) | 2014-09-26 | 2020-02-11 | University Of Massachusetts | RNA-modulating agents |
CN113652416A (zh) | 2014-10-06 | 2021-11-16 | 奥驰亚客户服务有限公司 | 烟草植物中腋芽生长的遗传控制 |
KR20170083063A (ko) | 2014-11-17 | 2017-07-17 | 모레 매트릭스 인코포레이티드 | 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법 |
EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
CA2971425A1 (en) | 2014-12-16 | 2016-06-23 | Pioneer Hi-Bred International, Inc. | Restoration of male fertility in wheat |
US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
WO2016115490A1 (en) | 2015-01-16 | 2016-07-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of dux4 |
WO2016116870A1 (en) | 2015-01-21 | 2016-07-28 | Basf Se | Plants having increased tolerance to herbicides |
US10485196B2 (en) | 2015-02-03 | 2019-11-26 | The Institute Of Genetics And Developmental Biology Chinese Academy Of Scinces | Rice plants with altered seed phenotype and quality |
WO2016124918A1 (en) | 2015-02-03 | 2016-08-11 | The Institute Of Genetics And Developmental Biology | Plants with increased seed size |
BR112017016688B1 (pt) | 2015-02-04 | 2024-01-23 | Basf Plant Science Company Gmbh | Método para aumentar a resistência fúngica, método para a produção de um produto e método para criar uma planta resistente a fungos |
GB201501941D0 (en) | 2015-02-05 | 2015-03-25 | British American Tobacco Co | Method |
JP6929791B2 (ja) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | エピゲノム編集のための組成物および方法 |
WO2016128470A1 (en) | 2015-02-11 | 2016-08-18 | Basf Se | Herbicide-resistant hydroxyphenylpyruvate dioxygenases |
GB201502409D0 (en) | 2015-02-13 | 2015-04-01 | British American Tobacco Co | Method |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
BR112017019343A2 (pt) | 2015-03-12 | 2018-05-02 | Moerae Matrix Inc | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas |
EP3271467A1 (en) | 2015-03-18 | 2018-01-24 | Basf Se | Recombinant microorganism for improved production of fine chemicals |
EP3283502A4 (en) | 2015-04-07 | 2019-04-03 | The General Hospital Corporation | METHODS FOR REACTIVATION OF GENES ON INACTIVE X CHROMOSOME |
WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
CA2985458A1 (en) | 2015-05-09 | 2016-11-17 | Two Blades Foundation | Late blight resistance gene from solanum americanum and methods of use |
KR20180011313A (ko) | 2015-06-04 | 2018-01-31 | 바스프 에스이 | 정제 화학약품의 개선된 제조를 위한 재조합 미생물 |
KR20180011324A (ko) | 2015-06-12 | 2018-01-31 | 바스프 에스이 | 알라닌의 개선된 제조를 위한 재조합 미생물 |
WO2016210241A1 (en) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
AU2016287499B2 (en) | 2015-06-29 | 2022-08-04 | Caris Science, Inc. | Therapeutic oligonucleotides |
WO2017019918A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
EP4285912A3 (en) | 2015-09-25 | 2024-07-10 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
WO2017062790A1 (en) | 2015-10-09 | 2017-04-13 | Two Blades Foundation | Cold shock protein receptors and methods of use |
EP3362571A4 (en) | 2015-10-13 | 2019-07-10 | Duke University | GENOMIC ENGINEERING WITH TYPE I CRISPRISMS IN EUKARYOTIC CELLS |
WO2017068544A1 (en) | 2015-10-22 | 2017-04-27 | Basf Se | Plants having increased tolerance to herbicides |
CA3007424A1 (en) | 2015-11-05 | 2017-05-11 | Children's Hospital Los Angeles | "mobilizing leukemia cells" |
CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
US11058709B1 (en) | 2015-12-04 | 2021-07-13 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
CA3007152A1 (en) | 2015-12-07 | 2017-06-15 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
US10907160B2 (en) | 2016-01-05 | 2021-02-02 | Ionis Pharmaceuticals, Inc. | Methods for reducing LRRK2 expression |
JP2019509721A (ja) | 2016-02-04 | 2019-04-11 | キュリス,インコーポレイテッド | 突然変異体スムースンド及びその使用方法 |
WO2017138986A1 (en) | 2016-02-09 | 2017-08-17 | Cibus Us Llc | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
WO2017147087A1 (en) | 2016-02-25 | 2017-08-31 | The Brigham And Women's Hospital, Inc. | Treatment methods for fibrosis targeting smoc2 |
WO2017156535A1 (en) | 2016-03-11 | 2017-09-14 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
CA3013799A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Methods of modulating keap1 |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
WO2017161357A1 (en) | 2016-03-18 | 2017-09-21 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
HUE056865T2 (hu) | 2016-03-30 | 2022-03-28 | Basf Se | N-Butil-akrilát fermentatív elõállítása alkohol-acil-transzferáz enzim segítségével |
WO2017184500A1 (en) | 2016-04-18 | 2017-10-26 | Bloomsburg University of Pennsylvania | Compositions and methods of delivering molecules to plants |
CA3022475A1 (en) | 2016-04-29 | 2017-11-02 | Basf Plant Science Company Gmbh | Improved methods for modification of target nucleic acids |
EP3054014A3 (en) | 2016-05-10 | 2016-11-23 | BASF Plant Science Company GmbH | Use of a fungicide on transgenic plants |
AU2017266411B2 (en) | 2016-05-20 | 2023-06-08 | BASF Agro B.V. | Dual transit peptides for targeting polypeptides |
WO2017202774A1 (en) | 2016-05-24 | 2017-11-30 | Basf Se | Method for controlling ppo resistant weeds |
EP3464597B1 (en) | 2016-05-25 | 2022-08-03 | Caris Science, Inc. | Oligonucleotide probe selection method and uses thereof |
BR112018074101A2 (pt) | 2016-05-26 | 2019-03-06 | Nunhems Bv | plantas produtoras de fruto sem semente |
WO2017219017A1 (en) | 2016-06-17 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
JP2019524074A (ja) | 2016-06-22 | 2019-09-05 | ノース カロライナ ステート ユニバーシティNorth Carolina State University | 植物における窒素の使用効率及び/又は窒素利用効率を増加させる方法 |
EP3481430A4 (en) | 2016-07-11 | 2020-04-01 | Translate Bio Ma, Inc. | NUCLEIC ACID CONJUGATES AND USES THEREOF |
CN109688807B (zh) | 2016-07-15 | 2023-04-28 | 巴斯夫欧洲公司 | 具有增加的除草剂耐受性的植物 |
US11149030B2 (en) | 2016-07-27 | 2021-10-19 | BASF Agro B.V. | Plants having increased tolerance to herbicides |
WO2018019845A1 (en) | 2016-07-29 | 2018-02-01 | Basf Se | Method for controlling ppo resistant weeds |
WO2018019842A1 (en) | 2016-07-29 | 2018-02-01 | Basf Se | Method for controlling ppo resistant weeds |
EP3278667A1 (en) | 2016-08-05 | 2018-02-07 | Basf Se | Method for controlling ppo-inhibitor resistant weeds |
WO2018024696A1 (en) | 2016-08-05 | 2018-02-08 | Basf Se | Method for controlling ppo resistant weeds |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
WO2018024695A1 (en) | 2016-08-05 | 2018-02-08 | Basf Se | Method for controlling ppo resistant weeds |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
EP3281523A1 (en) | 2016-08-09 | 2018-02-14 | Basf Se | Method for controlling ppo resistant weeds |
EP3281524A1 (en) | 2016-08-09 | 2018-02-14 | Basf Se | Method for controlling ppo resistant weeds |
BR112019001934B1 (pt) | 2016-08-09 | 2022-09-20 | Basf Se | Método para controlar o crescimento de ervas daninhas, uso de compostos de fórmula (i) e uso da composição |
EP3497213B1 (en) | 2016-08-09 | 2023-10-18 | Vib Vzw | Cellulose synthase inhibitors and mutant plants |
AU2017311446B2 (en) | 2016-08-09 | 2022-04-28 | Basf Se | Method for controlling PPO resistant weeds |
US20190166841A1 (en) | 2016-08-09 | 2019-06-06 | Basf Se | Method for Controlling PPO Resistant Weeds |
EP3281525A1 (en) | 2016-08-09 | 2018-02-14 | Basf Se | Method for controlling ppo resistant weeds |
EP3522898A4 (en) | 2016-10-06 | 2020-05-27 | Ionis Pharmaceuticals, Inc. | METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS |
EP3523439A1 (en) | 2016-10-07 | 2019-08-14 | Altria Client Services LLC | Composition and methods for producing tobacco plants and products having reduced tobacco-specific nitrosamines (tsnas) |
CA3037046A1 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
EP3555299A1 (en) | 2016-12-16 | 2019-10-23 | Two Blades Foundation | Late blight resistance genes and methods of use |
BR112019012763A2 (pt) | 2016-12-20 | 2019-12-10 | Basf Agro Bv | vegetais ou partes de vegetais, semente capaz de germinação em um vegetal, célula de vegetal ou capaz de regenerar um vegetal, célula de vegetal, produto de vegetal, progênie ou vegetal descendente, métodos para o controle de ervas daninhas e a produção de um vegetal, molécula de ácido nucléico, cassete de expressão, vetor, polipeptídeo de ppo mutada isolado, método para a produção de um produto de vegetal e produto de vegetal |
JP2020503066A (ja) | 2016-12-27 | 2020-01-30 | インバイオス エン.フェー. | シアル酸付加化合物のin vivo合成 |
WO2018140214A1 (en) | 2017-01-24 | 2018-08-02 | Pioneer Hi-Bred International, Inc. | Nematicidal protein from pseudomonas |
US20190367937A1 (en) | 2017-02-09 | 2019-12-05 | Fujian Agriculture And Forestry University | Expression of a phosphate transporter for improving plant yield |
WO2018165564A1 (en) | 2017-03-09 | 2018-09-13 | Ionis Pharmaceuticals, Inc. | Morpholino modified oligomeric compounds |
AU2018256435A1 (en) | 2017-04-20 | 2019-11-07 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
US11445692B2 (en) | 2017-05-15 | 2022-09-20 | Equi-Nom Ltd. | Quantitative trait loci (QTL) associated with shatter resistant capsules in sesame and uses thereof |
WO2019023587A1 (en) | 2017-07-28 | 2019-01-31 | Two Blades Foundation | POTYVIRUS RESISTANCE GENES AND METHODS OF USE |
AU2018318231A1 (en) | 2017-08-18 | 2020-02-13 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | MODULATORS OF SMAD7 EXPRESSION |
US11104912B2 (en) | 2017-09-11 | 2021-08-31 | Altria Client Services Llc | Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers |
US11999953B2 (en) | 2017-09-13 | 2024-06-04 | The Children's Medical Center Corporation | Compositions and methods for treating transposon associated diseases |
TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
WO2019108619A1 (en) | 2017-11-28 | 2019-06-06 | Two Blades Foundation | Methods and compositions for enhancing the disease resistance of plants |
AR114807A1 (es) | 2017-11-29 | 2020-10-21 | Basf Se | Plantas que tienen una mayor tolerancia a herbicidas |
CN111788306A (zh) | 2017-12-20 | 2020-10-16 | 巴斯夫欧洲公司 | 核酸酶以及用于制备和使用其的方法 |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
US11034969B2 (en) | 2017-12-22 | 2021-06-15 | Altria Client Services Llc | Plant comprising recombinant polynucleotides encoding a pigment regulatory transcription factor with a tissue-preferred promoter |
CN107868123B (zh) | 2017-12-25 | 2020-05-12 | 中国农业科学院作物科学研究所 | 一种同时提高植物产量和抗性的基因及其应用 |
CA3087266A1 (en) | 2018-01-09 | 2019-07-18 | Cibus Us Llc | Shatterproof genes and mutations |
CN111954464A (zh) | 2018-01-12 | 2020-11-17 | 双刃基金会 | 秆锈病抗性基因及使用方法 |
RU2020127049A (ru) | 2018-01-15 | 2022-02-17 | Айонис Фармасьютикалс, Инк. | Модуляторы экспрессии dnm2 |
WO2019142099A1 (en) | 2018-01-17 | 2019-07-25 | Basf Se | Plants having increased tolerance to herbicides |
WO2019158911A1 (en) | 2018-02-14 | 2019-08-22 | Institute Of Genetics And Developmental Biology Chinese Academy Of Sciences | Methods of increasing nutrient use efficiency |
EP3759127A4 (en) | 2018-03-02 | 2022-03-30 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN |
TWI840345B (zh) | 2018-03-02 | 2024-05-01 | 美商Ionis製藥公司 | Irf4表現之調節劑 |
EP3768694A4 (en) | 2018-03-22 | 2021-12-29 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
EP4051799A2 (en) | 2018-03-30 | 2022-09-07 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers for targeted activaton of t cell-mediated immunity |
EP4062774B1 (en) | 2018-04-03 | 2024-03-20 | Altria Client Services LLC | Composition and methods for producing tobacco plants and products having increased phenylalanine and reduced tobacco-specific nitrosamines (tsnas) |
EP3772928A4 (en) | 2018-04-06 | 2021-12-29 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
CA3094020A1 (en) | 2018-04-11 | 2019-10-17 | Ionis Pharmaceuticals, Inc. | Modulators of ezh2 expression |
EP3784779A1 (en) | 2018-04-26 | 2021-03-03 | Basf Se | Lipase enzymes |
WO2019211143A1 (en) | 2018-05-03 | 2019-11-07 | Basf Se | Amylase enzymes |
UY38225A (es) | 2018-05-09 | 2019-11-29 | Ionis Pharmaceuticals Inc | Compuestos y métodos para reducir de la expresión de atxn3 |
KR20210008498A (ko) | 2018-05-09 | 2021-01-22 | 아이오니스 파마수티컬즈, 인코포레이티드 | Fxi 발현을 감소시키기 위한 화합물 및 방법 |
WO2019219933A1 (en) | 2018-05-17 | 2019-11-21 | Vib Vzw | An engineered combinatorial module of transcription factors to boost production of monoterpenoid indole alkaloids |
CA3103429A1 (en) | 2018-06-14 | 2019-12-19 | Don W. Cleveland | Compounds and methods for increasing stmn2 expression |
US11291176B2 (en) | 2018-06-15 | 2022-04-05 | Nunhems B.V. | Seedless watermelon plants comprising modifications in an ABC transporter gene |
TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
CN112805004A (zh) | 2018-07-02 | 2021-05-14 | 艾珀特玛治疗公司 | 向人脂肪细胞靶向递送治疗剂 |
WO2020023737A1 (en) | 2018-07-25 | 2020-01-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn2 expression |
US20210292766A1 (en) | 2018-08-29 | 2021-09-23 | University Of Massachusetts | Inhibition of Protein Kinases to Treat Friedreich Ataxia |
CA3110656A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
US20210317467A1 (en) | 2018-09-07 | 2021-10-14 | Basf Plant Science Copmany Gmbh | Improved method for the production of high levels of pufa in plants |
CA3110651A1 (en) | 2018-09-07 | 2020-03-12 | Basf Plant Science Company Gmbh | Improved method for the production of high levels of pufa in plants |
EP3867391A1 (en) | 2018-10-18 | 2021-08-25 | Basf Se | Method for the production of acrylic acid or salts thereof |
TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
BR112021008967A2 (pt) | 2018-11-15 | 2021-08-17 | Ionis Pharmaceuticals, Inc. | moduladores da expressão de irf5 |
WO2020127975A1 (en) | 2018-12-20 | 2020-06-25 | Basf Plant Science Company Gmbh | Native delivery of biomolecules into plant cells using ionic complexes with cell-penetrating peptides |
US20220017931A1 (en) | 2019-01-22 | 2022-01-20 | Basf Se | Method for production of 4-cyano benzoic acid or salts thereof |
WO2020154466A1 (en) | 2019-01-24 | 2020-07-30 | Altria Client Services Llc | Tobacco plants comprising reduced nicotine and reduced tobacco specific nitrosamines |
JP2022519532A (ja) | 2019-01-31 | 2022-03-24 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Yap1発現のモジュレーター |
GB201902253D0 (en) | 2019-02-19 | 2019-04-03 | Univ Court Univ Of Glasgow | Methods for optogenetic manipulation of stomatal function |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
JP7492526B2 (ja) | 2019-02-27 | 2024-05-29 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Malat1発現のモジュレーター |
WO2020185737A1 (en) | 2019-03-11 | 2020-09-17 | Basf Se | Amylases and methods for making and using them |
CA3133614A1 (en) | 2019-03-14 | 2020-09-17 | Rothamsted Research Limited | Genetically modified plants with enhanced drought tolerance |
WO2020193534A2 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Amylase enzymes |
EP3947665A2 (en) | 2019-03-25 | 2022-02-09 | Basf Se | Amylase enzymes |
WO2020193532A1 (en) | 2019-03-25 | 2020-10-01 | Basf Se | Cleaning composition having amylase enzymes |
WO2020205463A1 (en) | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
WO2020229241A1 (en) | 2019-05-10 | 2020-11-19 | Basf Se | Regulatory nucleic acid molecules for enhancing gene expression in plants |
BR112021026248A2 (pt) | 2019-06-27 | 2022-03-03 | Two Blades Found | Molécula de ácido nucleico isolada que codifica uma proteína atrlp23 engenheirada, proteína atrlp23 engenheirada, cassete de expressão, vetor, célula hospedeira, planta ou célula vegetal, métodos para fazer uma proteína atrlp23 engenheirada, para fazer uma molécula de ácido nucleico que codifica uma proteína atrlp23 engenheirada e para intensificar a resistência de uma planta |
CA3143570A1 (en) | 2019-06-27 | 2020-12-30 | Basf Plant Science Company Gmbh | Methods for transformation of fungal spores |
WO2021011348A1 (en) | 2019-07-12 | 2021-01-21 | The Regents Of The University Of California | Plants with enhanced resistance to bacterial pathogens |
EP3956450A4 (en) | 2019-07-26 | 2022-11-16 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR MODULATION OF GFAP |
KR20220062517A (ko) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
WO2021032881A1 (en) | 2019-08-22 | 2021-02-25 | Basf Se | Amylase variants |
BR112022004545A2 (pt) | 2019-09-12 | 2022-05-31 | Basf Se | Métodos para aumentar a expressão derivada de um promotor vegetal e produzir uma planta, construção de expressão recombinante, vetor de expressão, célula ou planta transgênica, cultura de células transgênicas e usos |
WO2021058691A1 (en) | 2019-09-26 | 2021-04-01 | Basf Se | Method for the production of beta-alanine or salts thereof |
WO2021069387A1 (en) | 2019-10-07 | 2021-04-15 | Basf Se | Regulatory nucleic acid molecules for enhancing gene expression in plants |
CN114787365A (zh) | 2019-12-03 | 2022-07-22 | 巴斯夫欧洲公司 | 用于在植物中增强基因表达的调节性核酸分子 |
EP4077683A1 (en) | 2019-12-16 | 2022-10-26 | BASF Agricultural Solutions Seed US LLC | Precise introduction of dna or mutations into the genome of wheat |
WO2021122080A1 (en) | 2019-12-16 | 2021-06-24 | BASF Agricultural Solutions Seed US LLC | Improved genome editing using paired nickases |
US20230075913A1 (en) | 2019-12-16 | 2023-03-09 | BASF Agricultural Solutions Seed US LLC | Codon-optimized cas9 endonuclease encoding polynucleotide |
AU2021225957A1 (en) | 2020-02-28 | 2022-09-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating SMN2 |
US20230139192A1 (en) | 2020-03-04 | 2023-05-04 | Basf Se | Shuttle vector for expression in e. coli and bacilli |
US20230212593A1 (en) | 2020-03-04 | 2023-07-06 | Basf Se | Method for the production of constitutive bacterial promoters conferring low to medium expression |
BR112022021333A2 (pt) | 2020-05-01 | 2022-12-13 | Ionis Pharmaceuticals Inc | Compostos e métodos para modular atxn1 |
KR20230012530A (ko) | 2020-05-15 | 2023-01-26 | 바스프 에스이 | 이소프레노이드의 생산을 위한 개선된 방법 |
MX2022016338A (es) | 2020-06-29 | 2023-01-24 | Ionis Pharmaceuticals Inc | Compuestos y metodos para modular la plp1. |
US11730133B2 (en) | 2020-10-21 | 2023-08-22 | Equi-Nom Ltd | High yield sesame |
TW202227101A (zh) | 2020-11-18 | 2022-07-16 | 美商Ionis製藥公司 | 用於調節血管收縮素原表現之化合物及方法 |
IL303800A (en) | 2020-12-18 | 2023-08-01 | Ionis Pharmaceuticals Inc | Factor XII Modulation Compounds and Methods |
CN117917951A (zh) | 2021-05-11 | 2024-04-23 | 双刃基金会 | 用于抗病性功能测试的植物抗病基因文库的制备方法 |
US11753644B2 (en) | 2021-06-18 | 2023-09-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing IFNAR1 expression |
WO2023012342A1 (en) | 2021-08-06 | 2023-02-09 | Kws Vegetables B.V. | Durable downy mildew resistance in spinach |
WO2023031161A1 (en) | 2021-09-03 | 2023-03-09 | BASF Agricultural Solutions Seed US LLC | Plants having increased tolerance to herbicides |
US11395470B1 (en) | 2021-09-14 | 2022-07-26 | Equi-Nom Ltd. | Sesame with high oil content and/or high yield |
WO2023043220A1 (ko) | 2021-09-16 | 2023-03-23 | 주식회사 큐마인 | Wfdc2의 발현을 조절하는 안티센스 화합물 |
CA3233676A1 (en) | 2021-09-30 | 2023-04-06 | The Sainsbury Laboratory | Plant disease resistance genes against stem rust and methods of use |
WO2023067192A1 (en) | 2021-10-21 | 2023-04-27 | Consejo Superior De Investigaciones Cientificas (Csic) | Methods for improving abiotic stress resistance |
WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
AU2022422286A1 (en) | 2021-12-22 | 2024-07-04 | BASF Agricultural Solutions Seed US LLC | Improved screening method for genome edited events |
WO2023131616A1 (en) | 2022-01-05 | 2023-07-13 | Vib Vzw | Means and methods to increase abiotic stress tolerance in plants |
WO2023131637A1 (en) | 2022-01-06 | 2023-07-13 | Vib Vzw | Improved silage grasses |
WO2023144199A1 (en) | 2022-01-26 | 2023-08-03 | Vib Vzw | Plants having reduced levels of bitter taste metabolites |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024044352A1 (en) | 2022-08-26 | 2024-02-29 | The General Hospital Corporation | Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure |
WO2024083579A1 (en) | 2022-10-20 | 2024-04-25 | Basf Se | Regulatory nucleic acid molecules for enhancing gene expression in plants |
WO2024089011A1 (en) | 2022-10-26 | 2024-05-02 | BASF Agricultural Solutions Seed US LLC | Excision of recombinant dna from the genome of plant cells |
WO2024094678A2 (en) | 2022-11-02 | 2024-05-10 | Basf Se | Improved method for the production of natural vanillin |
US20240182561A1 (en) | 2022-11-04 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
WO2024107765A2 (en) | 2022-11-14 | 2024-05-23 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
WO2024126113A1 (en) | 2022-12-12 | 2024-06-20 | BASF Agricultural Solutions Seed US LLC | Plants having increased tolerance to herbicides |
WO2024132947A1 (en) | 2022-12-19 | 2024-06-27 | Basf Se | New cellulase promoters for fungal protein production |
WO2024156593A1 (en) | 2023-01-27 | 2024-08-02 | Basf Se | New genomic integration site for fungal protein and fine chemicals production |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4503151A (en) * | 1980-12-10 | 1985-03-05 | Research Corporation | Recombinant cDNA construction method and hybrid nucleotides useful in cloning |
US4873191A (en) * | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4882279A (en) * | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
DE3788914T2 (de) * | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere. |
US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
WO1990014092A1 (en) * | 1989-05-18 | 1990-11-29 | Cell Genesys, Inc. | Single-strand site-directed modification of mammalian genes in vivo |
EP0626012B1 (en) * | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
EP0672159B1 (en) * | 1992-04-24 | 2005-12-28 | Sri International | Homologous sequence targeting in eukaryotic cells |
EP0656747A4 (en) * | 1992-08-21 | 1997-05-07 | Univ California | COMPOSITION AND METHOD FOR CHANGING DNA SEQUENCES BY HOMOLOGOUS RECOMBINATION. |
JPH08510900A (ja) * | 1993-03-31 | 1996-11-19 | ハイブライドン インコーポレイテッド | 改良された抗インフルエンザ活性を有する修飾オリゴヌクレオチド |
-
1994
- 1994-12-09 JP JP51636795A patent/JP3585238B2/ja not_active Expired - Fee Related
- 1994-12-09 NZ NZ278490A patent/NZ278490A/en unknown
- 1994-12-09 AT AT95905337T patent/ATE196311T1/de not_active IP Right Cessation
- 1994-12-09 DK DK95905337T patent/DK0733059T3/da active
- 1994-12-09 CA CA002178729A patent/CA2178729A1/en not_active Abandoned
- 1994-12-09 EP EP95905337A patent/EP0733059B1/en not_active Expired - Lifetime
- 1994-12-09 PT PT95905337T patent/PT733059E/pt unknown
- 1994-12-09 AU AU13995/95A patent/AU691550B2/en not_active Ceased
- 1994-12-09 US US08/353,657 patent/US5565350A/en not_active Expired - Lifetime
- 1994-12-09 WO PCT/US1994/014181 patent/WO1995015972A1/en active IP Right Grant
- 1994-12-09 CN CN94194935A patent/CN1048254C/zh not_active Expired - Fee Related
- 1994-12-09 KR KR1019960703040A patent/KR100386337B1/ko not_active IP Right Cessation
- 1994-12-09 DE DE0733059T patent/DE733059T1/de active Pending
- 1994-12-09 DE DE69425903T patent/DE69425903T2/de not_active Expired - Fee Related
- 1994-12-09 ES ES95905337T patent/ES2149962T3/es not_active Expired - Lifetime
-
1996
- 1996-09-09 US US08/709,982 patent/US5756325A/en not_active Expired - Fee Related
-
1997
- 1997-12-02 US US08/982,866 patent/US5871984A/en not_active Expired - Fee Related
-
1998
- 1998-08-22 CN CN98118786A patent/CN1117866C/zh not_active Expired - Fee Related
-
2000
- 2000-12-04 GR GR20000402677T patent/GR3034988T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1142829A (zh) | 1997-02-12 |
DE69425903T2 (de) | 2001-02-15 |
EP0733059A4 (en) | 1997-05-21 |
DE733059T1 (de) | 1997-08-28 |
DE69425903D1 (de) | 2000-10-19 |
GR3034988T3 (en) | 2001-03-30 |
KR960706500A (ko) | 1996-12-09 |
WO1995015972A1 (en) | 1995-06-15 |
KR100386337B1 (ko) | 2004-03-24 |
JPH09506511A (ja) | 1997-06-30 |
US5871984A (en) | 1999-02-16 |
DK0733059T3 (da) | 2000-10-16 |
ATE196311T1 (de) | 2000-09-15 |
EP0733059B1 (en) | 2000-09-13 |
CN1117866C (zh) | 2003-08-13 |
CN1048254C (zh) | 2000-01-12 |
ES2149962T3 (es) | 2000-11-16 |
US5565350A (en) | 1996-10-15 |
US5756325A (en) | 1998-05-26 |
AU691550B2 (en) | 1998-05-21 |
CA2178729A1 (en) | 1995-06-15 |
PT733059E (pt) | 2001-03-30 |
EP0733059A1 (en) | 1996-09-25 |
AU1399595A (en) | 1995-06-27 |
NZ278490A (en) | 1998-03-25 |
CN1215755A (zh) | 1999-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3585238B2 (ja) | 真核細胞における部位特異的突然変異誘発のための化合物および方法 | |
US7053195B1 (en) | Locked nucleic acid containing heteropolymers and related methods | |
CN110770342B (zh) | Dna被编辑了的真核细胞的制造方法、和在该方法中使用的试剂盒 | |
JP3832851B2 (ja) | 人工トランスポゾンのinvitroにおける転位 | |
AU740702B2 (en) | Cell-free chimeraplasty and eukaryotic use of heteroduplex mutational vectors | |
AU2004284374B2 (en) | DNA cloning vector plasmids and methods for their use | |
CA2258090A1 (en) | Chimeric mutational vectors having non-natural nucleotides | |
JP7078946B2 (ja) | ゲノム編集方法 | |
WO2018030208A1 (ja) | 遺伝子ノックイン細胞の作製方法 | |
US20030148352A1 (en) | Intracellular generation of single-stranded DNA | |
JP5947309B2 (ja) | オリゴヌクレオチドを用いたdnaの標的改変 | |
EP1533375B1 (en) | Method of transferring mutation into target nucleic acid | |
JP2024006091A (ja) | tracrRNAユニット、及びゲノム編集方法 | |
KR20050021366A (ko) | 표적 핵산내 돌연변이 도입 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040531 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040720 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040803 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080813 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |